Fraction size in radiation therapy for breast conservation in early breast cancer (Review) by Hickey, Brigid E. et al.
Cochrane Database of Systematic Reviews
Fraction size in radiation therapy for breast conservation in
early breast cancer (Review)
Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP, See AM
Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP, See AM.
Fraction size in radiation therapy for breast conservation in early breast cancer.
Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD003860.
DOI: 10.1002/14651858.CD003860.pub4.
www.cochranelibrary.com
Fraction size in radiation therapy for breast conservation in early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
6BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
23DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
58DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 1 Local recurrence-free survival
(LR-FS). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
Analysis 1.2. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 2 LR-FS by dose. . . . 60
Analysis 1.3. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 3 Cosmesis (fair/poor). . 61
Analysis 1.4. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 4 Overall survival (OS). 62
Analysis 1.5. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 5 Acute skin radiation
toxicity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
Analysis 1.6. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 6 Late skin toxicity. . . 63
Analysis 1.7. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 7 Late subcutaneous toxicity
(fibrosis)). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
Analysis 1.8. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 8 Telangiectasia. . . . 65
Analysis 1.9. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 9 Breast oedema. . . . 66
Analysis 1.10. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 10 Breast shrinkage. . 67
Analysis 1.11. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 11 Ischaemic heart disease
(left-sided tumours). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
Analysis 1.12. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 12 Rib fractures. . . 68
Analysis 1.13. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 13 Breast cancer-specific
survival. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
Analysis 1.14. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 14 Relapse-free survival. 70
70ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
74APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
77WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
77HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
77CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
78DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
78SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
78DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
79INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iFraction size in radiation therapy for breast conservation in early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Fraction size in radiation therapy for breast conservation in
early breast cancer
Brigid E Hickey1,2, Melissa L James3, Margot Lehman2,4, Phil N Hider5, Mark Jeffery3, Daniel P Francis6 , Adrienne M See1
1Radiation OncologyMater Service, Princess Alexandra Hospital, Brisbane, Australia. 2School of Medicine, The University of Queens-
land, Brisbane, Australia. 3Canterbury Regional Cancer andHaematology Service, ChristchurchHospital, Christchurch,NewZealand.
4Radiation Oncology Unit, Princess Alexandra Hospital, Brisbane, Australia. 5Department of Population Health, University of Otago,
Christchurch, Christchurch, New Zealand. 6School of Public Health and Social Work, Queensland University of Technology, Brisbane,
Australia
Contact address: Brigid E Hickey, Radiation Oncology Mater Service, Princess Alexandra Hospital, 31 Raymond Terrace, Brisbane,
Queensland, 4101, Australia. brigid.hickey@health.qld.gov.au. hickmenn@bigpond.net.au.
Editorial group: Cochrane Breast Cancer Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 7, 2016.
Review content assessed as up-to-date: 23 May 2015.
Citation: Hickey BE, James ML, Lehman M, Hider PN, Jeffery M, Francis DP, See AM. Fraction size in radiation therapy
for breast conservation in early breast cancer. Cochrane Database of Systematic Reviews 2016, Issue 7. Art. No.: CD003860. DOI:
10.1002/14651858.CD003860.pub4.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Shortening the duration of radiation therapy would benefit women with early breast cancer treated with breast conserving surgery. It
may also improve access to radiation therapy by improving efficiency in radiation oncology departments globally. This can only happen
if the shorter treatment is as effective and safe as conventional radiation therapy. This is an update of a Cochrane Review first published
in 2008 and updated in 2009.
Objectives
To assess the effect of altered radiation fraction size for women with early breast cancer who have had breast conserving surgery.
Search methods
We searched the Cochrane Breast Cancer Specialised Register (23 May 2015), CENTRAL (The Cochrane Library 2015, Issue 4),
MEDLINE (Jan 1996 to May 2015), EMBASE (Jan 1980 to May 2015), the WHO International Clinical Trials Registry Platform
(ICTRP) search portal (June 2010 toMay 2015) and ClinicalTrials.gov (16 April 2015), reference lists of articles and relevant conference
proceedings. No language or publication constraints were applied.
Selection criteria
Randomised controlled trials of altered fraction size versus conventional fractionation for radiation therapy in women with early breast
cancer who had undergone breast conserving surgery.
Data collection and analysis
Two authors performed data extraction independently, with disagreements resolved by discussion. We sought missing data from trial
authors.
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Main results
We studied 8228 women in nine studies. Eight out of nine studies were at low or unclear risk of bias. Altered fraction size (delivering
radiation therapy in larger amounts each day but over fewer days than with conventional fractionation) did not have a clinically
meaningful effect on: local recurrence-free survival (Hazard Ratio (HR) 0.94, 95% CI 0.77 to 1.15, 7095 women, four studies, high-
quality evidence), cosmetic outcome (Risk ratio (RR) 0.90, 95% CI 0.81 to 1.01, 2103 women, four studies, high-quality evidence)
or overall survival (HR 0.91, 95% CI 0.80 to 1.03, 5685 women, three studies, high-quality evidence). Acute radiation skin toxicity
(RR 0.32, 95% CI 0.22 to 0.45, 357 women, two studies) was reduced with altered fraction size. Late radiation subcutaneous toxicity
did not differ with altered fraction size (RR 0.93, 95% CI 0.83 to 1.05, 5130 women, four studies, high-quality evidence). Breast
cancer-specific survival (HR 0.91, 95% CI 0.78 to 1.06, 5685 women, three studies, high quality evidence) and relapse-free survival
(HR 0.93, 95% CI 0.82 to 1.05, 5685 women, three studies, moderate-quality evidence) did not differ with altered fraction size. We
found no data for mastectomy rate. Altered fraction size was associated with less patient-reported (P < 0.001) and physician-reported
(P = 0.009) fatigue at six months (287 women, one study). We found no difference in the issue of altered fractionation for patient-
reported outcomes of: physical well-being (P = 0.46), functional well-being (P = 0.38), emotional well-being (P = 0.58), social well-
being (P = 0.32), breast cancer concerns (P = 0.94; 287 women, one study). We found no data with respect to costs.
Authors’ conclusions
We found that using altered fraction size regimens (greater than 2 Gy per fraction) does not have a clinically meaningful effect on local
recurrence, is associated with decreased acute toxicity and does not seem to affect breast appearance, late toxicity or patient-reported
quality-of-life measures for selectedwomen treated with breast conserving therapy. These are mostly women with node negative tumours
smaller than 3 cm and negative pathological margins.
P L A I N L A N G U A G E S U M M A R Y
Fraction size in radiation therapy for breast conservation in early breast cancer
Review question
We asked if giving fewer radiation treatments (using a higher radiation dose at each visit) was as effective as the conventional 25 to 30
radiation treatments for women with early breast cancer who have breast conserving therapy (keep their breast).
Background
Breast cancer is the most common cancer diagnosed in women, with one in eight women in the United States and Australia, and one
in nine women in the United Kingdom being diagnosed with the condition by age 85 years. Breast conserving therapy (removing the
tumour but keeping an intact breast) has proven to be as effective as mastectomy (removing the breast tissue) in terms of survival for
women with cancer confined to the breast (or the local lymph nodes, or both), as long as a five to six-week course of radiation therapy
is delivered. This involves 25 to 30 visits to a radiation oncology department. Without radiation therapy after breast conserving surgery
there is a significant risk of breast cancer returning in the breast (local recurrence). Furthermore, for every local recurrence avoided
with radiation, one death is avoided at 15 years. Many women prefer breast conservation which has resulted in an increased demand
for radiation services. Giving fewer daily radiation treatments (fractions) would be beneficial to women if this has the same effect on
tumour control and survival, and cosmetic outcome. In order to reduce the number of treatments, the radiation dose delivered per
fraction is increased. This may also reduce demand on radiation resources and be more convenient for women.
Study characteristics
Nine studies, involving 8228 women, were included in this review. Most of the women in the studies (91%) had tumours 3 cm or less
in size, all had complete removal of the tumour on pathology and 68% had no evidence of cancer in their lymph nodes. Where the
breast size was known, 83% had small or medium breasts.
Key results
The evidence is current up to May 2015. Local recurrence was not different for women having fewer treatments (four fewer local
relapses per 1000 (where the true value may be anywhere between 16 fewer to 10 more local relapses per 1000)). Breast appearance
was not different for women undergoing fewer treatments (31 fewer fair/poor breast appearance per 1000 (where the true value may be
anywhere between 59 fewer to 3 more per 1000 with fair/poor breast appearance)). Survival was not altered by having fewer treatments
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(13 fewer deaths per 1000 (where the true value could be between 31 fewer to 5 more deaths per 1000)) and there was no significant
difference in late skin toxicity (4more episodes of toxicity per 1000; where the true value may be anywhere between 14 fewer to 36 more
episodes of toxicity per 1000) or radiation toxicity. Acute skin toxicity is decreased with fewer treatments (326 fewer events per 1000
(where the true value may be anywhere between 264 fewer to 374 fewer acute skin toxicity events per 1000)). This review indicates
that for women who fit these criteria, using fewer radiation treatments after tumour removal gives the same cancer control, with less
skin reaction at the time and the likely the same side-effects in the long term.
Quality of the evidence
We found high quality evidence for the following outcomes: local recurrence-free survival, breast appearance, toxicity, overall survival
and breast cancer-specific survival. We found moderate quality evidence for relapse-free survival, and no data for mastectomy rate
(mastectomy may be required because of local recurrence or unacceptable treatment-related toxicity) or costs.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for women treated with breast conserving therapy for early breast cancer
Patient or population: women treated with breast conserving therapy for early breast cancer
Setting: cancer centres
Intervention: hypof ract ionated radiat ion therapy
Comparison: convent ionally f ract ionated radiat ion therapy
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with convention-
ally fractionated radia-
tion therapy
Risk with hypofraction-
ated radiation therapy
Local recurrence-f ree
survival (LR-FS) at 10
years
Study populat ion HR 0.94
(0.77 to 1.15)
7095
(4 RCTs)
⊕⊕⊕⊕
HIGH
70 per 1,0001 66 per 1,000
(54 to 80)
Cosmesis
assessed with fair/ poor
on 4-point scale,
follow-up: range 42
months-12 years
Study populat ion RR 0.90
(0.81 to 1.01)
2103
(4 RCTs)
⊕⊕⊕⊕
HIGH
311 per 1,000 280 per 1,000
(252 to 314)
Mortality at 10 years Study populat ion HR 0.91
(0.80 to 1.03)
5685
(3 RCTs)
⊕⊕⊕⊕
HIGH
166 per 1,0001 153 per 1,000
(135 to 171)
Late subcutaneous tox-
icity
assessed with ≥ Grade
2 on 4-point scale,
follow-up: median 6
years
Study populat ion RR 0.93
(0.83 to 1.05)
5130
(4 RCTs)
⊕⊕⊕⊕
HIGH 2
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4 per 1,000 4 per 1,000
(3 to 4)
Breast cancer-specif ic
survival (BC-SS) at 10
years
Study populat ion HR 0.91
(0.78 to 1.06)
5685
(3 RCTs)
⊕⊕⊕⊕
HIGH
123 per 1,0001 113 per 1,000
(98 to 130)
Relapse-f ree survival
(RFS) at 10 years
Study populat ion HR 0.93
(0.82 to 1.05)
5685
(3 RCTs)
⊕⊕⊕©
MODERATE 3
224 per 1,0001 210 per 1,000
(188 to 234)
Mastectomy rate - not
measured
see comment see comment not est imable (studies) - We found no data with
respect to subsequent
mastectomy
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; HR: Hazard rat io; RR: risk rat io;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1The baseline risks for the control groups were calculated using 10-year event data f rom the included studies
2 No blinding for assessment of subject ive outcomes (for 5% of events only)
3Stat ist ical test ing as well as examinat ion of the forest plots suggested there was some heterogeneity
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B A C K G R O U N D
Description of the condition
This review is an update of a review previously published in the
Cochrane Database of Systematic Reviews 2009, Issue 11 on fraction
size in radiation therapy for breast conservation in early breast
cancer. Breast cancer is the most common cancer diagnosed in
women and the second most common cause of cancer death in
women. The lifetime risk to age 85 years of being diagnosed with
breast cancer for women living in Australia and the United States
is one in eight, and one in nine for women living in the United
Kingdom (AIHW 2006; ONS 1999; Ries 2004).
A significant change has occurred in the management of women
with early breast cancer (cancer confined to the breast and nearby
lymph nodes) over the last three decades. Previously most women
with early breast cancer underwent removal of the whole breast
(mastectomy). Evidence from several randomised controlled tri-
als (Fisher 1989; Veronesi 1990) and a meta-analysis of 36 tri-
als (EBCTCG 1995) confirms that long-term overall survival is
equivalent using breast conserving treatment compared with mas-
tectomy. Breast conserving treatment comprises removal of the
portion of the breast containing the tumour followed by radia-
tion therapy to the remaining breast tissue. Other studies have
shown that quality of life is enhanced in women who undergo
breast conserving treatment (Al-Ghazal 2000). Consequently,
breast conserving treatment has become the recommended op-
tion for women with early breast cancer in many Western coun-
tries (NBCC 2001; NIH 1991). Breast conserving surgery now
accounts for 70% of breast cancer operations in some series
(Chouillet 1994) and, as a result, demand for radiation therapy
services has increased. Some health services have struggled to meet
this increasing demand because of a shortage of trained personnel
and expensive radiation treatmentmachines (Ash 2000;Mackillop
1994).
Description of the intervention
Radiation following breast conserving surgery involves treatment
to the breast with ionising radiation. Typically the radiation is
delivered over a period of five to six weeks using a standard 2 Gy
(Gray) radiation dose per fraction, in 25 to 30 treatment episodes,
to a total dose of 50 to 60 Gy.
How the intervention might work
Recently there has been interest from cancer service providers in
shortening the overall treatment time. One method of achieving
this is to increase the size of each fraction thereby decreasing the
total number of fractions required. For example, case series using
40 Gy in 15 fractions or 36 Gy in 12 fractions have been reported
(Ash 2000; Olivotto 1996). Shorter fractionation schedules have
the advantages of using machine and staff time more efficiently
and reducing patient inconvenience.
Concerns have been raised, however, as to whether shorter frac-
tionation schedules have equivalent outcomes in terms of local
tumour control, breast appearance (cosmesis), late toxicity, overall
survival and patient satisfaction. The concern with larger fraction
sizes is based on radiobiological principles which state that the
fraction size is the dominant factor in determining late side ef-
fects. The aim of conventional fractionation at 2 Gy per fraction
is to decrease the rate of late tissue damage whilst aiming to max-
imise tumour control with acceptable acute toxicity (Hall 1994).
Higher fraction size could lead to increased scarring and retraction
of breast tissue as well as skin atrophy (thinning) and telangiectasia
(dilated blood vessels).
Why it is important to do this review
The optimal fractionation schedule is not well-established (
Whelan 1993) but evidence from clinical trials suggests that the
results of shorter schedules may be equivalent with respect to local
control and cosmesis (Whelan 2002a; Yarnold 1994). Published
trials to date have been too small to detect differences in cancer
recurrence rates reliably.
If a shorter fractionation schedule was shown to provide equiva-
lent outcomes for women this could lead to more efficient use of
radiation services and more expedient treatment for women with
early breast cancer.
O B J E C T I V E S
To assess the effect of altered radiation fraction size for women
with early breast cancer who have had breast conserving surgery.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only randomised controlled trials were considered for inclusion.
We required the comparisons to be unconfounded, that is the treat-
ment given to the intervention and comparator groups could dif-
fer only in relation to the fractionation schedule used. Trials where
the participants received adjuvant treatment in the form of che-
motherapy, monoclonal antibody treatment, or hormonal therapy
were eligible providing these treatments were applied equally to
6Fraction size in radiation therapy for breast conservation in early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
all study groups. Published and unpublished studies were eligible.
Outcomes were not used as criteria for considering studies for in-
clusion in this review.
Types of participants
Women with histologically confirmed early breast cancer who had
undergone breast conserving surgery. Early breast cancer is de-
fined as invasive adenocarcinoma restricted to the breast, plus or
minus the local lymph nodes, which can be removed surgically
(EBCTCG 2011), that is T1-2, N0-1, M0 (Fleming 1997).
Surgery could include lumpectomy, wide local excision, quadran-
tectomy, or segmental resection; with or without axillary dissec-
tion, node sampling, or sentinel node biopsy. If a study included
the relevant population as a subgroup and the outcomes relating
to this group were reported separately, we included those partici-
pants eligible for this review (e.g. Saha 2009).
Types of interventions
Postoperative radiation to the breast alone and delivered using
conventional fractionation (1.8 to 2 Gy per fraction) versus post-
operative radiation to the breast alone at greater than 2 Gy per
fraction. The dose prescribed and the prescription point had to be
clearly identified. We specified the dose in accordance with the In-
ternational Commission on Radiation Units and Measurements’
(ICRU 50)(Jones 1994) recommendations with respect to dose,
dose specification point and dose per fraction. Where possible, we
converted data found in studies into this form. Partial breast irra-
diation was excluded because it is the subject of another Cochrane
systematic review (see: Lehman 2014).
Types of outcome measures
Primary outcomes
1. Local recurrence-free survival (LR-FS) in the ipsilateral
breast (i.e. events defined as cancer detected in the same breast
where the cancer had been diagnosed).
2. Appearance or cosmesis (objective and subjective) of the
treated breast.
Secondary outcomes
1. Overall survival (OS; time from date of randomisation to
death from any cause, or number of deaths from any cause).
2. Toxicity (including acute and late effects of radiation
therapy and chemotherapy-related toxicity); we used individual
protocol-based definitions.
3. Breast cancer-specific survival (BC-SS; events were: death
due to breast cancer).
4. Relapse-free survival (RFS; events included local recurrence,
loco-regional recurrence, distant metastasis and death).
5. Mastectomy rate (salvage following local recurrence or
unacceptable toxicity).
6. Quality of life (trial-specific instruments).
7. Costs (to women and health services).
Search methods for identification of studies
Searches were not limited by language or date.
Electronic searches
We searched the following databases:
1. Cochrane Breast Cancer Specialised Register (23 May
2015). The details of search strategies used by the Group for the
identification of studies and the procedure used to code
references are outlined in their module (Breast Cancer Group
2016). We extracted studies coded as ’early’ and ’radiotherapy’
and ’dose intensity’ in the Specialised Register for consideration;
2. CENTRAL (The Cochrane Library 2015, Issue 4). See
Appendix 1 for search strings;
3. MEDLINE (OVID) (1966 to May 2015). See Appendix 2
for search strings;
4. EMBASE (OVID) (1980 to May 2015). See Appendix 3
for search strings;
5. WHO International Clinical Trials Registry Platform
(ICTRP) Search Portal (apps.who.int/trialsearch/) for the period
10 June 2010 until May 2015. See Appendix 4;
6. ClinicalTrials.gov (clinicaltrials.gov) on 16 April 2015. See
Appendix 5;
7. Grey literature (opengrey.org) on 06 May 2015. See
Appendix 6.
Searching other resources
We handsearched the following conference proceedings:
1. American Society of Oncology: 1995-2010;
2. European Society for Therapeutic Radiation Oncology:
1990, 1993, 2000-2010, 2012;
3. American Society for Therapeutic Radiation: 2011, 2012,
2014;
4. We searched reference lists of published studies and review
articles.
Data collection and analysis
Selection of studies
In the previous versions and 2015 review update, two or more
authors checked the titles and abstracts retrieved by the searches
(previous versions: four authors; 2015 reviewupdate: BHandMJ).
Two authors (BH and MJ) independently assessed the full text of
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all studies we thought relevant to the review with differences being
resolved by discussion.
Data extraction and management
Two authors (BH and ML) performed data extraction indepen-
dently, with disagreements being resolved by discussion. We en-
tered data into Review Manager 5.3 (RevMan 2014) for analysis.
Where data were limited, we requested further information from
the authors of the original studies. We received data from the au-
thors of START A 2008; START B 2008 and Owen 2006a. Data
for local recurrence events was derived from percentages (Whelan
2002b) where raw numbers were not available (we assumed the
denominators used were the numbers in each arm of the trial).
Where there were two experimental arms using altered fraction
size (Owen 2006a; START A 2008), we combined the number of
events and denominators to form a single experimental arm.
We calculated the log rank statistic (O-E) and its variance for
time-to-event outcomes using an Excel spreadsheet developed by
Matthew Sydes (Cancer Division) in collaboration with theMeta-
analysis Group of the MRC Clinical Trials Unit, London (Sydes
2007). For STARTB2008, to deriveO-E and variance for: LR-FS,
OS, BC-SS and RFS, we used Method four (where HR, number
of events in each arm and the randomisation is 1:1). We used
Method four to derive O-E and variance for OS (Whelan 2002b).
We usedMethod six to derive O-E and variance for LR-FS (Owen
2006a; START A 2008) (where HR and total number of events
are available and randomisation need not be 1:1), OS, RFS and
BC-SS (START A 2008). We used Method eleven to derive LR-
FS and R-FS (Whelan 2002b; data extracted from the curve where
numbers at risk are available). Method sevenwas used to derive O-
E and variance for BC-SS (Whelan 2002b; where P value, events
in each arm available and randomisation ratio is 1:1).
We reported cosmetic outcome using a four-point scale (see ad-
ditional Table 1: Owen 2006a; Taher 2004; Whelan 2002b).
This was dichotomised and those who had fair/poor results were
counted as having events. For Owen 2006a and Whelan 2002b,
we derived figures from percentages given in the text.
Acute toxicity: twodifferent five-point scaleswere used (Cox 1995;
NCI); any woman who hadGrade II toxicity ormore was scored as
having an event. Although they are both five-point scales, theNCI
does not always use all five grades. After examining the descriptions
for each grade in the two different scales, we chose to report any
women with Grade 2 toxicity ormore as having an event (see Table
2 and Table 3).
Late radiation therapy (RT) toxicity (telangiectasia, breast oedema,
subcutaneous toxicity): any woman who had Grade 2 toxicity or
more was scored as having an event.
Rib fractures: we reported radiologically confirmed rib fractures
(excluding those related to metastases and trauma).
We reported ischaemic heart disease for those women with left-
sided tumours, and those with pre-existing heart disease were ex-
cluded.
Pulmonary fibrosis was confirmed radiologically.
We converted the radiation doses to the equivalent dose in 2 Gy
fractions (EQD2 ) (Maciejewski 1986; Withers 1983), using the
formula: EQD2 =D (d + alpha/beta/2 + alpha/beta), whereD= to-
tal dose, d = dose per fraction and alpha/beta = 4Gy (Owen 2006b;
see Table 4). This was to facilitate comparison of radiation doses
given at differing dose per fraction. We converted brachytherapy
(radiation sources applied directly to the body) to the biological
equivalent dose (BED) using the method of Stitt 1992.
We reported the P values for any difference in the mean score
(measured at baseline and six months) for patient-reported qual-
ity of life measures scored using FACT-B (Brady 1997; Webster
2003).
Assessment of risk of bias in included studies
Two review authors (BH, ML) categorised the risk of bias of each
eligible study using the system outlined in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011a). DF
resolved any discrepancies that arose. BH constructed and ML
reviewed ’Risk of bias’ tables for the included studies, with any
discrepancies resolved by discussion. We constructed a ’Risk of
bias’ graph with review authors’ judgements about each method-
ological quality item (presented as percentages across all included
studies). We separated assessment of risk of bias into subjective
(e.g. cosmesis) and objective outcomes (e.g. LR-FS).
We planned sensitivity analysis on the basis of study quality, which
was to be performedwith andwithout trials of low quality to assess
the effect of quality on the results.
Measures of treatment effect
We presented results so that a result less than one favoured the
experimental arm (hypofractionation). Summary statistics for di-
chotomous measures were presented as risk ratios (RR) with 95%
confidence intervals (CI) (Deeks 2003). Summary statistics for
continuous variables were presented as mean differences (MD),
where possible. We used Mantel-Haenszel methods to calculate
pooled risk ratios (Greenland 1985; Mantel 1959). Where possi-
ble, we used the HR to present time-to-event data for the end-
points of LR-FS, OS, RFS, with 95% CI.
We deemed that a HR equal to or less than 0.75 and equal to or
greater than 1.25 was clinically meaningful. In the absence of clear
direction in the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Higgins 2011b), we made a pragmatic decision based on
our expert opinions as clinicians and used the Federal Drug Ad-
ministration (FDA) method (AHRQ 2011) to choose (post-hoc)
the minimal clinically important difference (MID), using a figure
50% of the difference tested for in a randomised study (START A
2008). START A 2008 was powered to detect a 5% difference in
local relapse, so we chose 2.5% for our MID. We considered that
for LR-FS, BC-SS and OS, a reasonable MID was 2.5%, as this is
less than half the effect size sought in START A 2008 (5%), and
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was chosen to be deliberately conservative. Therefore if the upper
limit of the confidence interval indicated the intervention was less
then 2.5% worse than the control, we concluded non-inferiority.
Unit of analysis issues
Because the unit of analysis was the participant, we did not have
any unit of analysis issues.
Dealing with missing data
We contacted the study authors for any missing data.
Assessment of heterogeneity
We assessed heterogeneity both visually and statistically using the
Chi2 test (Altman 1992;Walker 1988) and the Higgins I2 statistic
(Higgins 2002; Higgins 2003). We acknowledge that with few
studies the statistical power to detect heterogeneity is low.
Assessment of reporting biases
We used funnel plots to assess for publication bias where we had
five or more studies.
Data synthesis
We extracted data from the trials according to the intention-to-
treat (ITT) principle where possible and determined a weighted
average treatment effect using the fixed-effect model to combine
results (Mantel 1959) in RevMan 5.3 (RevMan 2014). Where it
was possible to derive the log rank statistic (O-E) and its variance
from the presented data, we used Peto’s method to estimate the
pooled hazard ratio (HR). Our comparison of interest was altered
fraction size (hypofractionation) versus conventional fractiona-
tion, so when analysing the trials we combined the two different
’fractionation dose’ altered arms of the Owen 2006a and START
A 2008 trials as described in the Cochrane Handbook for System-
atic Reviews of Interventions (Deeks 2011). In the future, if more
information becomes available, separate analysis may be possible
to investigate a dose effect for different fractionation schedules.
Acute radiation toxicity
1. Acute skin toxicity was reported for FAST 2011; START A
2008; START B 2008 and Taher 2004.
Late radiation toxicity
1. Late skin toxicity (Whelan 2002b) was assessed at five and
ten years using a five-point scale (Winchester 1992) (see
additional Table 5) and analysed as a dichotomous outcome
using RR. The results were dichotomised into: none or mild
versus moderate, marked or severe. We reported the women who
had ≥ Grade II toxicity for each arm (percentages given in text
converted to numbers).
2. Ischaemic heart disease for women with left-sided tumours
without pre-existing heart disease (at median follow-up 9.3 to
9.9 years) was reported in full (START A 2008; START B 2008).
3. Rib fractures, those confirmed and excluding those
secondary to trauma or metastatic disease (at median follow-up
9.3 to 9.9 years) were reported in full (START A 2008; START
B 2008).
4. Induration (fibrosis) and subcutaneous toxicity:
We assumed that induration and subcutaneous toxicity, reported
by or at five years by Owen 2006a and Whelan 2002b respec-
tively and at ten years (START A 2008; START B 2008) repre-
sented the same outcome and could, therefore, be combined for
analysis. Whelan 2002b used the RTOG/EORTC five-point late
radiation morbidity scale, with the women assessed by a trained
nurse (Winchester 1992) (see Additional Table 5). Owen 2006a
used a four-point trial-specific scale (see Additional Table 6) and
the outcome was assessed by physicians. In START A 2008 and
START B 2008, the women were assessed by physicians using a
four-point scale (see Table 7) and the results dichotomised: those
women with Grade II toxicity or above had an event recorded.
The results were dichotomised in the Owen 2006a report but re-
ported in full in Whelan 2002b. In order to combine the results,
we dichotomised theWhelan 2002b results into two groups: those
with nil or slight late radiation toxicity, and those who had any
greater toxicity; that is the women who had scores of two or more
were counted as having toxicity. No participant in Whelan 2002b
had severe (Grade 4) toxicity.
Marked or any change in breast appearance: results were di-
chotomised in the report (Owen 2006a).
If sufficient data becomes available in future updates we will use
recommended methods to collect and combine the data. We will
use the mean difference method unless trials have reported results
on different scales, in which case we will use a standardised mean
difference to summarise data (Deeks 2011).
’Summary of findings’ table
Using the GRADE approach, we created a ’Summary of findings’
table based on the following outcomes.
1. Local recurrence-free survival
2. Cosmesis
3. Overall survival (called mortality in Summary of Findings
Table)
4. Toxicity (late sub-cutaneous toxicity/fibrosis)
5. Breast cancer-specific survival
6. Relapse-free survival
7. Mastectomy rate
Refer to Summary of findings for the main comparison. To calcu-
late the absolute risk for the control group for time-to-event out-
comes in the ’Summary of Findings’ table, we estimated the event
rate at a specific time point (10 years for LR-FS, Mortality, BC-SS,
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and RFS) from the Kaplan-Meier curves or reported event rates
in the included studies. These estimated values were entered in
GRADEproGDT software and the corresponding absolute risks
for the intervention group at 10 years were automatically popu-
lated by the software.
Subgroup analysis and investigation of heterogeneity
Weperformed subgroup analysis based on length of follow-up (4.2
years versus approximately 10 years) and by dose (experimental
arm < 50 Gy versus ≥ 50 Gy). In the two studies with two in-
tervention arms where the doses were both less than 50 Gy and
equal to or greater than 50 Gy (Owen 2006a; FAST 2011) and
the results were not reported by dose stratum, we were not able to
include them in the subgroup analysis.
If sufficient data become available in future updates we may per-
form subgroup analyses to investigate whether the effects of differ-
ent radiation fraction schedules differ depending on nodal status,
margin status, hormone receptor status, and tumour stage or other
factors which may become relevant in the future. If heterogeneity
is detected we will first check the data to ensure accuracy, in the
knowledge that with small study numbers, the power of statistical
testing for heterogeneity is low.
Sensitivity analysis
We did sensitivity analysis based on risk of bias, excluding studies
deemed at high risk of bias (Whelan 2002b).
R E S U L T S
Description of studies
Results of the search
For this update of the review, we screened a total of 2627 ab-
stracts, and considered 53 papers in full for eligibility. We ex-
cluded 25 full-text publications (see Characteristics of excluded
studies) and identified 28 new reports. Twelve reports referred
to five new included studies (FAST 2011; Patni 2012; Saha
2009; Shaitelman 2015; Taher 2004). Eight reports related
to three previously included studies (Owen 2006a; START A
2008; Whelan 2002b). Eight reports referred to five ongo-
ing studies (NCT00459628; NCT01266642; NCT00909818;
NCT01349322; NCT01413269). See Figure 1.
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Figure 1. Study flow diagram for updated review
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When combining studies from the previous review and this up-
date, 39 reports that met the inclusion criteria related to nine sep-
arate studies (FAST 2011; Owen 2006a; Patni 2012; Saha 2009;
Shaitelman 2015; START A 2008; START B 2008; Taher 2004;
Whelan 2002b). All of the trials had published their results at
different times with different periods of follow-up. We used the
most recent publication as the source for the review, supplement-
ing this with information from earlier reports if necessary. Thus,
for the Owen 2006a trial the primary source is Owen 2006a, with
10 other records found for this trial. The primary source for the
Whelan 2002b was Whelan 2002b, with six other reports found.
For STARTA 2008, there were seven records with one publication
(Sumo 2008) that was also relevant to START B 2008. START
B 2008 had two reports, FAST 2011 contained seven records,
Shaitelman 2015 had two records and Taher 2004 had one record
while Patni 2012 and Saha 2009 were reported only in one report
each in abstract form.
Included studies
The nine randomised trials included in this current version of the
review involved a total of 8228 women.
Participants
The women studied in this review were mostly women with early
breast cancer (6829/7553 (90.4%)) and 4580 out of 8010 (57%)
women were aged 50 or more where reported (FAST 2011; Owen
2006a; STARTA2008; STARTB2008;Whelan2002b). Seventy-
two out of 287 (25%) of the women in Shaitelman 2015 and 59
women in Owen 2006a had Stage 0 early breast cancer or ductal
carcinoma in situ (DCIS): in total, 131/8228 (0.15%) women had
DCIS. Further, 6701/6701 (100%) of the women studied in this
review had negative pathological margins, where reported (FAST
2011; Saha 2009; Shaitelman 2015; START A 2008; START B
2008; Taher 2004; Whelan 2002b). Most tumours (3916/6600
(59%)) were 2 cm or less in size, where size was reported (FAST
2011; STARTA2008; STARTB2008;Whelan2002b) and4457/
4853 (91%) were 3 cm or less in size (FAST 2011; START A
2008; START B 2008). Women with T3 tumours (that is tumour
size greater than 5 cm) were eligible for the START A 2008 and
START B 2008 studies. They comprised 1.6% (22/1410) of the
women studied in Owen 2006a. T stage was not reported in
START A 2008 and START B 2008, but 15% (702/4451) of
women had tumours larger than 3 cm. Most women 5040/6135
(82%) studied in this review, had small to medium breasts (where
breast size was reported) (FAST 2011; Owen 2006a; START A
2008; STARTB2008;Whelan2002b), in Shaitelman 2015 (those
with cup size D or less).Most women (5332/7824 (68%)) studied
in this review were node negative where reported (FAST 2011;
Owen 2006a; START A 2008; START B 2008; Whelan 2002b)
and most women (7675/8188 (93.7%)) studied were treated with
breast conserving surgery. Saha 2009 included 131 women with
early breast cancer, we included the 47 women treated with breast
conserving surgery, where the results were reported separately.
Interventions
Radiation therapy dose
Shaitelman 2015; Taher 2004 and Whelan 2002b compared two
different fractionation regimens (42.5 Gy in 16 fractions and 50
Gy in 25 fractions). Owen 2006a compared three fractionation
regimens (39 Gy in 13 fractions, 42.9 Gy in 13 fractions, and
50 Gy in 25 fractions). START A 2008 compared three regimens
(41.6 Gy in 13 fractions, 39 Gy in 13 fractions and 50 Gy in 25
fractions). Patni 2012 and START B 2008 compared two frac-
tionation regimens (40 Gy in 15 fractions and 50 Gy in 25 frac-
tions). FAST 2011 compared three regimens: 30 Gy in five frac-
tions, 28.5 Gy in five fractions and 50 Gy in 25 fractions. Saha
2009 compared 30 Gy in 5 fractions versus 50 Gy in 25 fractions.
See Table 4 for comparison of BED and EQD2.
The RT delivered in Shaitelman 2015 used techniques to:
1. improve dose heterogeneity (wedging, 3D compensation or
intensity modulated RT (IMRT)); they specified that dose
received did not exceed 108% of prescribed dose;
2. reduce lung dose (respiratory gating);
3. improve accuracy (CT planning).
Boost to tumour bed
Overall, 3454/7715 (44.7%) of the women studied received a
boost (an extra dose delivered to the tumour bed) (Owen 2006a;
Patni 2012; Saha 2009; Shaitelman2015; STARTA2008; START
B 2008, Taher 2004). In the experimental arm, 1390/3581
(38.8%) of women received a boost and in the control arm 972/
2772 (35%) received a boost (data excludes Owen 2006a and Saha
2009, where boost was not reported by study arm; see Table 8).
Owen 2006a: 1051/1410 (75%) were treated with a boost of 14
Gy at 90% in seven fractions. The authors did not report how
many women in each arm received a boost. For women with neg-
ative margins, if the clinician felt it was appropriate, there was
a sub-randomisation to boost or no boost from January 1986 to
May 1994. After this, all 687 participants were offered an elective
boost (see additional Table 8). The boost dose delivered was not
reported in Patni 2012. The planning target volume (PTV) for the
boost was clearly defined in Shaitelman 2015. START A 2008:
for women treated with breast conservation, 771/1269 (61%) of
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women in the experimental arm and 381/631 (60%) of women
in the control arm received a boost of 10 Gy in five fractions using
electrons. In total, 1152/1900 (61%) received a boost. Each par-
ticipating department specified in advance whether participants
enrolled from that site would receive radiotherapy boost (see ad-
ditional Table 8). START B 2008: for women treated with breast
conservation, 446/1018 (44%) and 422/1020 (41%) received a
10 Gy on five fraction boost using electrons. In total, 868/2038
(43%) received a boost. Each participating department specified
in advance whether participants enrolled from that site would re-
ceive radiotherapy boost (see additional Table 8). 15/30 women in
Taher 2004 (all the conventional arm) received a boost (see Table
8).
No women in FAST 2011 or Whelan 2002b were treated with
boosts.
Regional nodal irradiation
318/2236 (1.3%) of women in START A 2008 and 161/2215
(7%) women in START B 2008 were treated with regional nodal
RT.
Co-interventions
In total, 5566/7513 (74%) women received hormonal manipula-
tion (mostly tamoxifen) and 1709/8188 (21%) received chemo-
therapy. No women in FAST 2011 received adjuvant chemother-
apy, 704 received tamoxifen and 102 an aromatase inhibitor. In to-
tal, 196/1410 women received chemotherapy and 1074/1410 re-
ceived tamoxifen (numbers not given by study arm;Owen 2006a).
All (47/47) the women in Saha 2009 received chemotherapy. In
START A 2008 1758/2236 women received tamoxifen and 793/
2236women received chemotherapy and in START B2008 1928/
2215 women received tamoxifen and 491/2215 women received
chemotherapy. Taher 2004 treated 20/30 women with chemo-
therapy +/- hormonal therapy (not detailed by study arm) and
17/30 women received chemotherapy. One hundred and thirty-
six out of 1234 women in Whelan 2002b received chemotherapy,
28 out of 287 women in Shaitelman 2015 received neoadjuvant
chemotherapy and in total, 28/7800 (0.3%) of women received
neoadjuvant chemotherapy.
No co-interventions were reported in Patni 2012.
Quality assurance for radiation therapy
Both START A 2008 and START B 2008 had a rigorous quality
assurance programme to ensure the RT delivered was adherent to
protocol. In Shaitelman 2015 there was no trial-specific quality
assurance, other than institutional peer review process of radiation
therapy plans.
Outcomes
Local recurrence-free survival
LR-FS was reported at three and a half years (Saha 2009) and ten
years or more follow-up in Owen 2006a; START A 2008; START
B 2008 and Whelan 2002b.
Cosmesis
Participant-reported cosmetic outcome was reported in
Shaitelman 2015. Trained clinical trials nurses in Whelan 2002b
and a blinded physician panel in Shaitelman 2015 assessed global
cosmetic outcome using the four-point European Organisation
for Research and Treatment of Cancer (EORTC)Cosmetic Rating
System (Table 1). Of the women in the trial, 1220/1234 (98.8%)
had baseline cosmetic assessment. Cosmetic outcome was assessed
in the 735/1220 women with five years’ follow-up at the time
of assessment (Table 8). Cosmetic assessment was done for 1220
women at baseline and complete cosmetic data was reported for
735 women at five years (the time of interest for the outcome).
We have no indication that these women were different to the
remainder of those randomised. Triallists used a four-point scale
(Aaronson 1988) and the results were dichotomised as good or
excellent versus poor or fair (Table 1). The study reported these
results as percentages at three and five years with the total number
of women available for evaluation at each time period; as we did
not know the numbers in each arm, we were unable to derive fig-
ures from these data. In Taher 2004 and Saha 2009, the same four-
point scale was used to assess cosmesis, by an observer blinded to
treatment arm (Taher 2004) and the results were dichotomised as
in Whelan 2002b.
Owen 2006a reported breast cosmesis (median follow-up of 9.7
years, maximum 15 years) using a four-point scale (Table 9). A
total of 806 women (see Description of studies) were assessed and
the results were reported for a dichotomous outcome in the report.
We have no evidence that these womenwere substantially different
to the remainder of women in the trial: the reasons that women
were not followed up were not related to which arm they were ran-
domised to and were not related to whether they had local relapse
or late normal tissue side-effects from treatment. Quote: “Reasons
for non-availability were explored, and no evidence was observed
that this was associated with either the fractionation schedule or
to the probability of experiencing future normal tissue event or
local relapse (Owen 2006a).” The clinical assessment results were
dichotomised in the report into fair or poor versus good or excel-
lent (Owen 2006a).
Late change in breast appearance (assessed by blinded observers)
was reported in Owen 2006a; START A 2008 and START B
2008 and will be reported in FAST 2011 when the follow-up
is longer. Late change in breast appearance (photographic) was
assessed in the 1055 (START A 2008) and 923 (START B 2008)
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women who had both a photo at baseline and a follow-up photo
(START A 2008; START B 2008). Not all participants had a
photo at five years. Those with photos at two and five years were
combined when reported, and the authors did not report how
many had five-year follow-up. We have no evidence that these
women were substantially different to the remainder of women
in the trial. Quote: “There were no associations between score for
change in breast appearance (photographic) at two years or patient
demographic or treatment characteristics and whether or not the
participant had a five-year assessment (data not shown)”.
The primary outcome measure in Owen 2006a was late change
in breast appearance, which was assessed in the 1202 women who
had photographs available at baseline and at least a single follow-
up. Pairs of photographs were available as follows: 1128 at year
one, 1004 at year two, 525 at three years, 472 at four years, 765
at five years and 141 at 10 years, i.e. photographic follow-up was
reported for 63% of women at five years, and 11% at 10 years.
Overall survival
Overall survival was reported at ten years or more in START A
2008; START B 2008 and Whelan 2002b.
Acute skin radiation therapy toxicity
This was assessed using the RTOG CTCAE scoring system, a
five-point scale (Cox 1995) in FAST 2011; Patni 2012 and Taher
2004 (see Table 2). Acute toxicity was assessed in Shaitelman 2015
using NCI CTC version 4.0 (NCI; see Table 3). Those women
who experienced extensive moist desquamation were reported in
START A 2008 and START B 2008 (not reported by study arm).
Late radiation therapy toxicity
Owen 2006a reported late RT toxicity (un-blinded physician as-
sessment). Breast pain, oedema, subcutaneous fibrosis (indura-
tion), hyperpigmentation and telangiectasia were reported in Patni
2012 using RTOG CTCAE (Cox 1995). Late RT toxicity was as-
sessed in Saha 2009 using LENT-SOMA. Physicians (Shaitelman
2015) and trained nurses (Whelan 2002b) assessed late radiation
toxicity using the five-point Radiation Oncology Group/ EORTC
late radiation morbidity scale (Winchester 1992) to report skin
toxicity (Table 5). START A 2008 and START B 2008 reported
late RT toxicity: breast shrinkage, telangiectasia and breast oedema
was assessed annually (by physicians) in START A 2008 and
START B 2008 using a four-point scale. Any women with Grade
II toxicity or above were regarded as having an event.
Breast cancer-specific survival
BC-SS was reported at ten years or more in START A 2008;
START B 2008 and Whelan 2002b.
Relapse-free survival
RFS was reported at five years (Whelan 2002b) and at ten years
in START A 2008 and START B 2008.
Mastectomy rate
Mastectomy rates were not reported.
Quality of life
Quality of life was reported separately for 1129/2236 women in
START A 2008 and 1079/2215 women in START B 2008. Cen-
tres either opted in or out of participating in the quality-of-life
data collection, but the authors report that there was no differ-
ence in terms of RT planning or delivery between centres opting
to participate in the quality-of-life data collection or not. START
A 2008 and START B 2008 enrolled 2208 women in the qual-
ity-of-life assessments. The EORTC general cancer quality-of-life
scale (EORTCQLQ-C30; Aaronson 1993), breast cancer module
(BR23; Sprangers 1996), the Body Image Scale (BIS; Hopwood
2001) and the Hospital Anxiety and Depression Scale (HADS;
Zigmond 1983) were used to evaluate quality of life. The initial
publication describes the quality of life in the overall cohort of par-
ticipants, and was performed prior to breaking the randomisation
code. EORTCQLQ-C30 (Aaronson 1993) and BR23 (Sprangers
1996) were used, with a questionnaire at baseline, 6, 12, 24 and
60 months after RT. Shaitelman 2015 evaluated quality of life at
six months, using FACT-B (Brady 1997; Webster 2003), FACT-
G (Fairclough 1996), BIS (Hopwood 2001), Appearance Schemas
Inventory-Revised (ASI-R), and included both participant- and
physician-reported fatigue.
Costs
Costs were not reported.
Follow-up
FAST 2011 had amedian follow-up of 37.3 months. Owen 2006a
had a median follow-up of 9.7 years. Patni 2012 had a median
follow-up of sevenmonths. Saha 2009 reported at amedian follow-
up of 42 months. START A 2008 had a median follow-up of
9.3 years. START B 2008 had a median follow-up of 9.9 years.
Taher 2004 reported cosmesis at amedian follow-up of 22months.
Whelan 2002b had a median follow-up of 12 years. Shaitelman
2015 had “minimum follow up of six months.”
Shaitelman 2015; START A 2008 and Whelan 2002b addressed
non-inferiority: START A 2008 was an equivalence study. There
was inadequate detail to assess FAST 2011; Owen 2006a; Saha
2009 and Taher 2004 in this respect.
Further detail is available in the Characteristics of included studies
table.
14Fraction size in radiation therapy for breast conservation in early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Excluded studies
Fifty-three studies were reviewed in full, of these, 25 were excluded
(see Characteristics of excluded studies).
Studies awaiting classification
No studies await classification.
Ongoing studies
We identified five ongoing studies (see Characteristics of ongoing
studies).
Risk of bias in included studies
Summary assessment of risk of bias
For the outcome LR-FS, one study (Whelan 2002b) was deemed
at high risk of bias, but this was for subjective outcomes, so was
unlikely to have made this outcome at high risk of bias.
Cosmesis: one study (Whelan 2002b) was deemed at high risk of
bias, so we felt that for the domain of subjective outcomes this
outcome was at high risk of bias.
Overall survival: although two studies were deemed at high risk of
bias for some subjective outcomes, for this objective outcome, we
did not deem this outcome to be at high risk of bias.
Toxicity: no study reporting acute toxicity was deemed at high
risk of bias. Whelan 2002b was deemed at high risk of bias for no
blinding for subjective outcomes. We felt this would have had an
impact on the subjective outcome of late RT toxicity.
Cancer-specific survival: although Whelan 2002b was at high risk
of bias, we did not feel it would impact on this outcome.
Relapse-free survival: although Whelan 2002b was at high risk of
bias, we did not feel it would impact on this outcome.
Mastectomy rate: because this is an objective outcome, we did not
feel it was a high risk of bias.
Quality of life: the most reliable information would come from
patient-reported outcomes, so assessment of risk of bias for this
outcome would require information about how the data were col-
lected.
Costs: we did not feel this was at high risk of bias. RIsk of bias is
summarised in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Sequence generation was adequate for the following studies: FAST
2011; Shaitelman 2015; START A 2008; START B 2008 and
Whelan 2002b; for Owen 2006a this was unclear. We know for
FAST 2011; START A 2008, START B 2008 andWhelan 2002b
that this allocation was computer-generated. In Patni 2012; Saha
2009 and Taher 2004 there was inadequate detail with respect to
the method used for sequence generation.
Concealment of allocation was adequate for FAST 2011; Owen
2006a; STARTA 2008 and STARTB 2008. Computer-generated
permuted blocks were used in FAST 2011; START A 2008 and
START B 2008, which may allow prediction of the next randomi-
sation in the sequence. If those undertaking recruitment are not
aware that permuted blocks are being used, or the block size, then
this should not distort the recruitment. InWhelan 2002b the pro-
cess was central, although not explicitly described as concealed.
In Taher 2004 “closed envelopes” were used, but few details given
about the process used. In Saha 2009 there were no details given
about allocation concealment and inadequate details (“were ran-
domly assigned”) in Patni 2012 and Shaitelman 2015.
Blinding
Subjective outcomes
In Whelan 2002b, the participants and personnel were not men-
tioned as blinded (which was unlikely to have an impact on risk
of bias), but we judged Whelan 2002b to be at high risk of bias
because the likely lack of blinding (not mentioned) could have
introduced bias, particularly for assessment of cosmesis.
No details about blinding participants, personnel or assessors were
given in Patni 2012 and Saha 2009 for subjective outcomes so
these were deemed at unclear risk of bias.
In Shaitelman 2015 the participants and personnel were not men-
tioned as blinded (unlikely to have impact on risk of bias) and
although the assessors of acute toxicity were not blinded, the use of
a pre-specified toxicity scale reduced the associated risk of bias and
as quality of life used participant-reported outcomes, this domain
was judged to be at low risk of bias.
In FAST 2011; START A 2008 and START B 2008 the partici-
pants and personnel were not mentioned as blinded (unlikely to
have an impact on risk of bias). The assessors for photographic
appearance (FAST 2011; START A 2008; START B 2008) were
blinded which was most important for assessment of this subjec-
tive primary outcome, so we judged this at low risk of bias.
The assessors for photographic appearance (Owen 2006a) were
blindedwhichwasmost important for assessment of this subjective
primary outcome, so we judged this at low risk of bias. Clinical
assessments were not blinded (Owen 2006a), although they were
done by many people, which may potentially reduce the risk of
bias, so we judged this outcome to be at low risk of bias.
Although assessment of acute RT toxicity was not described as
blinded, the assessment of cosmetic outcome was blinded in Taher
2004 so we judged it to be at low risk of bias.
Objective outcomes
Blinding was not mentioned in Owen 2006a; START A 2008
or START B 2008 therefore it was probably not done. The time
points for clinical examinations were pre-specified, but the timing
for mammography was not reported in Owen 2006a; START A
2008 or STARTB 2008. There may have been lead time bias in di-
agnosis of local recurrence by un-blinded assessors, so we deemed
this outcome to be at unclear risk of bias for these studies. Blinding
of outcome assessors was not mentioned in Whelan 2002b, there-
fore probably not done, however, lead time bias in diagnosis of
local recurrence by un-blinded clinical assessors would be reduced
by the pre-specified mammography and clinical examination in-
tervals in Whelan 2002b, so we judged this outcome to be at low
risk of bias. In Taher 2004, the study was described as “open”,
which suggests it was not blinded, so judged to be at low risk of
bias. Blinding of assessors for objective outcomes: no details were
given in Saha 2009 (deemed at unclear risk of bias). No objective
outcomes were reported in Patni 2012 and Shaitelman 2015 (as
they were interim reports) and we deemed them to be at unclear
risk of bias. FAST 2011 was not blinded, but deemed to be at low
risk of bias.
Incomplete outcome data
Subjective outcomes
In Owen 2006a, 1202/1410 women had photos at both baseline
and at a later time point for the subjective cosmetic and toxicity
outcomes assessment. Reasons for attrition were not detailed, but
the number of women without a photo comprised less than 15%
of the cohort, so we judged it at low risk of bias. No details were
given with respect to attrition in Patni 2012 and Taher 2004. In
START A 2008, 1306/2236 enrolled in the photographic study:
assessed in 1055 participants with both a baseline and a follow-
up photograph. In START B 2008 1094/2215 enrolled in the
photographic study. For both START A 2008 and START B 2008
it is not clear why not all participants were enrolled, a source of
possible bias, so deemed at unclear risk of bias.
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Cosmetic outcome was assessed in 735/1220 women; those who
had follow-up to five years at the time of the initial trial report
(Whelan 2002b). It may be that the reason others did not have
five years follow-up is because they had not been in the trial long
enough, but it could also potentially be due to other reasons, per-
haps because of withdrawal or non-attendance, a possible source
of bias.
Late radiation toxicity was assessed in 752/1220 women at five
years. It may be that not all women had five years follow-up, but
this is not made clear (Whelan 2002b). The authors make the
point that most of the toxic effects of radiotherapy are evident by
five years follow-up.
For quality of life, the first 806/1410 women were selected to
enrol in the prospectively collected physician assessments (START
A 2008). In START B 2008, 1079/2215 enrolled in the quality-
of-life study. It is not clear how the participants enrolled in the
quality-of-life study were selected in both studies (STARTA2008;
START B 2008) so we deemed it to be at unclear risk of bias. No
details regarding attrition were given in Saha 2009, so this was
deemed at unclear risk of bias. For Shaitelman 2015, attrition was
clearly reported by study arm, so was deemed to be at low risk of
bias.
Objective outcomes
For FAST 2011 and Owen 2006a there were explicit details given
with respect to the numbers lost to follow-up and the reasons (per
treatment arm) given. Attrition was clearly described in START
A 2008 and START B 2008. In Whelan 2002b there was no
detail given regarding attrition, which is a potential source of bias.
No details regarding attrition were given in Saha 2009 or Taher
2004. There were no objective outcomes reported in the first study
reports of Patni 2012 and Shaitelman 2015, but they are likely to
be reported in the future, so we deemed them to be at unclear risk
of bias.
Selective reporting
All nine studies reported most of the outcomes detailed in the
methods, but we were not able to review the protocols. START
A 2008 and START B 2008 have not yet reported the health
economics consequences. Without comparing the reports with
the trial protocols, we could not be sure all outcomes had been
reported. Therefore we judged them all at unclear risk of bias.
Other potential sources of bias
Some studies were potentially biased by early reporting. Owen
2006a reported “minimum 5 year follow-up” for the subjective
primary outcome, so we judged it to be at unclear risk of bias.
The trial was stopped early because the START A 2008 and
START B 2008 trials started. For the subjective outcome assessed
photographically in both START A 2008 and START B 2008,
not all women were assessed at five years, so it is possible that only
a small number of women were assessed with five years’ follow-
up. We found no other sources of bias in FAST 2011; Saha 2009;
Shaitelman 2015 (so we judged this domain at low risk of bias).
There was inadequate detail given to judge Patni 2012 and Taher
2004 (deemed at unclear risk of bias). For Whelan 2002b, we did
not identify any other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
Hypofractionated radiation therapy compared to conventionally
fractionated radiation therapy for women treated with breast
conserving therapy for early breast cancer
In the results presented, ratios of treatment effects are given such
that HRs and RRs greater than 1.0 would indicate a beneficial
effect of altered fraction size over conventional fractionation (al-
though, as noted below, most of these results were not statistically
significant).
Primary outcomes
Local recurrence-free survival
We studied 442 local recurrences in 8050 women enrolled in six
studies.
For the comparison of altered fraction size versus conventional
fractionation we found that there was no clinically meaningful dif-
ference in local recurrence-free survival: HR 0.18 (95% CI 0.03
to 1.13) using observed events at 3.5 years and a HR 0.94 (95%
CI 0.77 to 1.15) using observed events at ten years (Analysis 1.1;
Figure 3). In absolute terms, this means 4 fewer local recurrences
per 1000 women at median follow-up ten years (95% CI 14 fewer
to 9 more). This represents 1.4% fewer local relapses (95% CI
1.6% fewer to 1.0%more) i.e. clinically meaningful harms or ben-
efits have been excluded. Specifically, altered fractionation is non-
inferior, not more than 2.5% worse than conventional fractiona-
tion. We found no evidence of heterogeneity: I2 = 0%, P = 0.54
(FAST 2011; Owen 2006a; Saha 2009; START A 2008; START
B 2008; Whelan 2002b).
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Figure 3. Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.1
Local recurrence-free survival (LR-FS).
Sensitivity analysis
Our results were robust to sensitivity analysis, we excluded studies
deemed at high risk of bias (Whelan 2002b). We found no dif-
ference in LR-FS: HR 0.94, 95% CI 0.76 to 1.17, P = 0.57. We
found no evidence of heterogeneity: I2 = 0%, P = 0.45.
Subgroup analysis
We did subgroup analysis by:
1. dose in the experimental arm < 50 Gy (START A 2008;
START B 2008; Whelan 2002b) and ≥ 50 Gy (Saha 2009): HR
0.89 (95% CI 0.70 to 1.14, P = 0.36; Analysis 1.2). We found
no heterogeneity: I2 = 0%, P = 0.53. We tested for statistical
difference between the subgroups (Chi2 = 0.27, I2 = 0%, P =
0.60) and found no difference between the subgroups;
2. length of follow-up 4.2 years versus 9.3 to 12 years. We
tested for statistical difference between the subgroups (I2 = 0%,
P = 0.58) and found no difference between the subgroups.
Cosmesis: appearance (objective and subjective) of the post-
treatment breast
We found no clinically meaningful difference in cosmesis for the
comparison of altered fraction size versus conventional fractiona-
tion (687 events, 2103 women, four studies): RR 0.90, 95% CI
0.81 to 1.01, P = 0.08 (Analysis 1.3; Figure 4). In absolute terms,
this represents 31 fewer women with poor or fair cosmetic out-
come per 1000 women treated with altered fraction size (95% CI
59 fewer to 3 more), i.e. clinically meaningful harms have been
excluded, but there may be meaningful benefit. We found little
evidence of heterogeneity, I2 = 15%, P = 0.32 (Owen 2006a; Saha
2009; Taher 2004; Whelan 2002b) (Analysis 1.3).
Figure 4. Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.3
Cosmesis (fair/poor).
19Fraction size in radiation therapy for breast conservation in early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sensitivity analysis
We excluded studies deemed at high risk of bias (Whelan 2002b).
We found that there may be an improvement in cosmesis for the
comparison of altered fraction size versus conventional fraction-
ation: RR 0.89, 95% CI 0.79 to 1.00, P = 0.06. There may be
some heterogeneity; I2 = 40%, P = 0.19.
START A 2008 reported photographic assessment of change in
breast appearance for those women treated with breast conserving
surgery (median follow-up of 6.0 years, maximum 6.2 years) using
a three-point scale. A total of 1055 women (see Description of
studies) were assessed at a mix of two and five years and were
dichotomised into mild or marked change or no change (figures
reported from text). For comparison of 41.6 Gy versus 50 Gy: HR
1.09 (95% CI 0.85 to 1.40, P = 0.62). For comparison of 39 Gy
versus 50 Gy: HR 0.69 (95% CI 0.52 to 0.91, P = 0.01).
START B 2008 reported photographic assessment of change in
breast appearance for those women treated with breast conserving
surgery (median follow-up of 5.1 years, maximum six years) using
a three-point scale. A total of 923 women (see Description of
studies) were assessed at a mix of two and five years and were
dichotomised into mild or marked change or no change (figures
reported from text): HR 0.83 (95% CI 0.66 to 1.04, P = 0.06).
Owen 2006a reported minimum five-year follow-up for any or
marked change in breast appearance and found no significant dif-
ference between the altered and conventional arms for any change:
RR 1.01 (95% CI 0.88 to 1.17, P = 0.86) or for marked change:
RR 1.24 (95% CI 0.77 to 2.00, P = 0.37). There was no differ-
ence inmoderate or marked breast distortion between the two trial
arms: RR 1.01 (95% CI 0.87 to 1.17, P = 0.90).
Secondary outcomes
Overall survival
We studied 991 deaths in 5685 women enrolled in three studies.
For the comparison of altered fraction size versus conventional
fractionation we found that there was no clinically meaningful ef-
fect on survival (median survival 9.3 to 9.9 years): HR 0.91 (95%
CI 0.80 to 1.03, P = 0.15; Analysis 1.4; Figure 5). In absolute
terms, there were 13 fewer deaths per 1000 women treated with
altered fraction size (95% CI 31 fewer to 5 more). This represents
1.3% fewer deaths (95% CI 3.1% fewer to 0.5% more) i.e. clin-
ically meaningful harms or benefits have been excluded. Specif-
ically, altered fractionation is non-inferior, not more than 2.5%
worse than conventional fractionation. We found little evidence
of heterogeneity, I2 = 19%, P = 0.29 (START A 2008; START B
2008; Whelan 2002b).
Figure 5. Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.4
Overall survival (OS).
Sensitivity analysis
Our results were robust to the exclusion of the study at high risk
of bias (Whelan 2002b) with a HR 0.90 (95% CI 0.78 to 1.04).
We found evidence of heterogeneity (I2 = 58%, P = 0.12).
Toxicity
This outcome covers acute and late effects of radiation therapy,
and chemotherapy-related toxicity.
Individual protocol-based definitions were used. Toxicity and late
effects were reported on assessable numbers.
Acute radiation skin toxicity
We studied acute radiation skin toxicity: 93 events were reported
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in 357 women enrolled in two studies (FAST 2011; Taher 2004).
Acute radiation toxicity was decreased by a clinically meaningful
amount in the altered fractionation arm: RR 0.32, 95% CI 0.22
to 0.45, P < 0.00001. There may be some heterogeneity: (I2 =
78%, P = 0.03; Analysis 1.5).
In Patni 2012 more acute skin toxicity was reported in the altered
fractionation arm at seven to 10 days (90% versus 66.3%, P =
0.204; figures from text).
“Two patients (both 50 Gy in 25 fractions) experienced an un-
usually marked acute skin reaction during their radiation therapy,
culminating in extensive moist desquamation” in START A 2008.
In START B 2008, “an unusually marked acute reaction during
radiotherapy was recorded for 16 patients (13 after 50 Gy), three
after 40 Gy.Of these, 14 cases were severe skin reactions (extensive
moist desquamation)” (not reported by study arm).
Late radiation toxicity
Late skin toxicity
Skin toxicity was reported at 12 years: there were 39 events in
455 women from one study (Whelan 2002b). No woman had
severe (Grade IV) skin toxicity. There was no clinicallymeaningful
increase in late RT skin toxicity for women treated with altered
fraction size RR 1.09 (95% CI 0.60 to 1.99, P = 0.77). In absolute
terms, three more per 1000 women treated with altered fraction
size (95%CI 15 fewer to 36more), i.e. clinicallymeaningful harms
or benefits have not been excluded. A test for heterogeneity was
not applicable with only one trial.
Late radiation subcutaneous toxicity
This did not differ at:
1. five years: RR 1.07 (95% CI 0.85 to 1.35, P = 0.55, 806
participants, 1 study (Owen 2006a) (Analysis 1.7);
2. 10 years: RR 0.89 (95% CI 0.78 to 1.02, P = 0.10, 4324
participants, 2 studies (START A 2008; START B 2008)
(Analysis 1.7).
We found no clinically meaningful difference in late radiation
subcutaneous toxicity (975 events in 5130 women, four studies)
for women treated with altered fraction size: RR 0.93, 95% CI
0.83 to 1.05, P = 0.24). In absolute terms, we found no fewer
women with late RT toxicity per 1000 women treated with altered
fraction size (95%CI 1 fewer to 0more), i.e. clinically meaningful
harms or benefits have been excluded.We found no heterogeneity:
I2 = 0%, P = 0.40. Test for subgroup difference, Chi2 = 1.81, I2 =
44.7%.
Late induration (sub-cutaneous fibrosis)
Measured at six months post RT this was “comparable” between
the two arms (Patni 2012; no figures given).
Telangiectasia
Telangiectasia (190 events in 4632 women, three studies) was re-
duced by a clinically meaningful amount in women treated with
altered fraction size compared with conventional fractionation:
RR 0.68 (95% CI 0.52 to 0.91, P = 0.009; Analysis 1.8). In ab-
solute terms, we found 16 fewer women developed telangiectasia
with altered fraction size (95% CI 4 fewer to 23 fewer). We found
no evidence of heterogeneity: I2 = 0%, P = 0.85. Telangiectasia,
measured at six months post RT was “comparable” between the
two arms (Patni 2012; no figures given).
Breast oedema
Breast oedema (332 events in 4140 women, three studies) was
reduced by a clinically meaningful amount in women treated with
altered fraction size compared with conventional fractionation:
RR 0.63 (95% CI 0.51 to 0.78, P < 0.0001; Analysis 1.9). In
absolute terms, 36 fewer women developed breast oedema with
altered fraction size (95% CI 21 fewer to 48 fewer) i.e. clinically
meaningful benefit has not been excluded. We found no evidence
of heterogeneity: I2 = 0%, P = 0.43. Breast oedema, measured
at six months post RT was “comparable” between the two arms
(Patni 2012; no figures given).
Breast shrinkage
Breast shrinkage (950 events in 3869 women, two studies) did
not differ by a clinically meaningful amount for the comparison
of altered fraction size versus conventional fractionation: RR 0.89
(95% CI 0.79 to 1.00, P = 0.04; Analysis 1.10). In absolute terms,
26 fewer women developed breast shrinkage with the use of al-
tered fraction size (95% CI 0 fewer to 49 fewer), i.e. clinically
meaningful harms or benefits have been excluded. We found no
evidence of heterogeneity: I2 = 0%, P = 0.54.
Ischaemic heart disease
Ischaemic heart disease in women with left-sided tumours (18
events in 4451 women, two studies: START A 2008; START B
2008) appeared reduced by a clinically meaningful amount for
the comparison of altered fraction size versus conventional frac-
tionation: RR 0.71 (95% CI 0.28 to 1.79, P = 0.47). In absolute
terms, one fewer woman developed ischaemic heart disease with
altered fraction size (95% CI 3 fewer to 4 more), i.e. clinically
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meaningful harms or benefits have not been excluded. There was
no heterogeneity: I2 = 0%, P = 0.80 (Analysis 1.11).
Rib fractures
Incidence of rib fractures (8 events in 5685 women, three studies:
START A 2008; START B 2008; Whelan 2002b) was reduced
by a clinically insignificant amount for the comparison of altered
fraction size versus conventional fractionation: RR 0.87 (95% CI
0.25 to 3.10, P = 0.83). In absolute terms, no fewer women de-
veloped rib fractures with altered fraction size (95% CI 1 fewer to
3 more) i.e. clinically meaningful harms or benefits have not been
excluded. There was no heterogeneity (I2 = 0%, P = 0.78; Analysis
1.12).
Breast cancer-specific survival
We studied 673 breast cancer deaths in 5685 women enrolled in
three studies (START A 2008; START B 2008; Whelan 2002b).
For the comparison of altered fraction size versus conventional
fractionation we found that there was no clinically meaningful
difference for the outcome of breast cancer-specific survival: HR
0.91 (95% CI 0.78 to 1.06, P = 0.21; Analysis 1.13; Figure 6). In
absolute terms, we found 10 fewer breast cancer deaths per 1000
women treated with altered fraction size (95% CI 25 fewer to 7
more). This represents 1.0% fewer breast cancer deaths (95% CI
2.5% fewer to 0.7% more) with altered fractionation i.e. clini-
cally meaningful harms or benefits have been excluded. Specifi-
cally, altered fractionation is non-inferior, not more than 2.5%
worse than conventional fractionation. We found no evidence of
heterogeneity: I2 = 0%, P = 0.42 (Analysis 1.13).
Figure 6. Forest plot of comparison: 1 Hypofractionation versus conventional fractionation, outcome: 1.13
Breast cancer-specific survival.
Relapse-free survival
We studied 870 relapses in 5685 women enrolled in three studies.
We found no clinically meaningful evidence that the use of hy-
pofractionation was detrimental to relapse-free survival (START
A 2008; START B 2008;Whelan 2002b): HR 0.93, 95% CI 0.82
to 1.05, P = 0.24 (Analysis 1.14). In absolute terms, we found 14
fewer relapses per 1000 women treated with altered fraction size
(95% CI 36 fewer to 10 more). This represents 1.4% fewer re-
lapses (95% CI 3.6% fewer to 1.0%more) i.e. clinically meaning-
ful harms or benefits have been excluded. Specifically, altered frac-
tionation is non-inferior, not more than 2.5% worse than conven-
tional fractionation. i.e. clinically meaningful benefits or harms
have been excluded. We found some evidence of heterogeneity, I
2 = 62% , P = 0.07.
Sensitivity analysis
These results were robust to sensitivity analysis. We excluded a
study deemed at high risk of bias (Whelan 2002b): HR 0.90, 95%
CI 0.78 to 1.03. We found evidence of heterogeneity: I2 = 74%,
P = 0.05.
Mastectomy rate
No data.
Quality of life (trial-specific instruments)
Shaitelman 2015 reported less patient-reported fatigue (P < 0.001)
and physician-reported fatigue (P = 0.009) for those women
treated with altered fraction size (figures from text) compared to
women treated with conventional fractionation at six months.
Shaitelman 2015 reported no difference in mean FACT-B scores
from baseline to six months for the following outcomes: physical
well-being (P = 0.46), functional well-being (P = 0.38), emotional
well-being (P = 0.58), social well-being (P = 0.32), FACT-G total
score (P = 0.73), breast cancer concerns (P = 0.94) and FACT-B
total score (P = 0.79).
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Costs (to women and health services)
No data.
D I S C U S S I O N
Summary of main results
We deemed that the Hazard Ratio of 0.75 or less and 1.25 or more
was clinically meaningful and if the 95% confidence interval was
greater than 0.75 or less and 1.25 or more, clinically meaningful
benefits or harms had not been excluded. For the outcomes of lo-
cal recurrence-free survival, overall survival, breast cancer-specific
survival and relapse-free survival, we determined (post-hoc) the
MID was 2.5%.
Local recurrence-free survival
For these comparisons, there appears to be no clinically meaning-
ful difference between the fractionation techniques for local re-
currence-free survival, and clinically meaningful benefits or harms
have been excluded.
Breast appearance (cosmesis)
For this comparison, there appears to be no clinically meaning-
ful difference between the fractionation techniques for cosmetic
outcome, and clinically meaningful benefits or harms have been
excluded.
Overall survival
For this comparison, there was no clinically meaningful difference
between the fractionation techniques, and clinically meaningful
benefits or harms have been excluded.
Acute RT skin toxicity
For these comparisons, there appears to be a clinically meaningful
reduction in acute RT toxicity when altered fraction size is used
versus conventional fractionation.
Late RT toxicity
For the comparison of altered fraction size versus conventional
fractionation for the following outcomes there was no difference:
late skin toxicity, late subcutaneous toxicity, breast shrinkage, is-
chaemic heart disease and rib fractures. Both telangiectasia and
breast oedema were reduced in women who had altered fraction
size, compared with conventional fractionation.
Breast cancer-specific survival
For this comparison, we found no clinically meaningful difference
between the fractionation techniques, and clinically meaningful
benefits or harms have been excluded.
Relapse-free survival
For this comparison, we found no clinically meaningful difference
between the fractionation techniques, and clinically meaningful
benefits or harms have been excluded.
Mastectomy rate
For this comparison, we found no data with respect to subsequent
mastectomy rates.
Quality of life
Shaitelman 2015 reported less patient- and physician-reported
fatigue for those women treated with altered fraction size.
Shaitelman 2015 reported no difference in mean FACT-B scores
for: physical well-being (P = 0.46), functional well-being (P =
0.38), emotional well-being (P=0.58), social well-being (P=0.32),
FACT-G total score (P = 0.73), breast cancer concerns (P = 0.94)
and FACT-B total score (P = 0.79).
Costs
We found no data with respect to costs or women’s preference for
either altered or conventional fractionation.
For women with early breast cancer, achieving and maintaining
local control in addition to maximising survival are the main goals
of management.Whilst conservative surgery followed by radiation
therapy allows preservation of the breast, the requirement for five
to six weeks of radiation therapy, which may only be available at
some distance from the woman’s residence, can be a burden. The
many costs involved (monetary and other) may mean that women
choose mastectomy over breast-conserving therapy to avoid the
necessity for radiation therapy (Nattinger 2001).
Shortening the duration of postoperative breast radiation would
provide the advantage of shorter disruption of normal activities
and less time away from home and family. Reducing the number
of fractions required would also free up radiation therapy machine
time. This may reduce waiting lists and improve timely access to
radiation therapy for other people with cancer. The ability to re-
duce the number of fractions required to treat women with early
breast cancer safely may, therefore, result in many benefits at a
personal, national and international level provided acceptable lo-
cal control, toxicity and survival can be maintained with this ap-
proach.
This review set out to explore whether shortened (altered fraction
size) regimens used to treat women who have had conservative
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surgery for early breast cancer can offer the same tumour control
and cosmetic results as longer fractionation regimens. We have
been able to include data from nine randomised controlled trials
that compared different fractionation schemes. The comparison
studied is altered fraction size (fraction size greater than 2 Gy)
versus conventional fractionation (2 Gy per fraction).
The findings of this review provide reassurance that the practice
of offering shortened radiation fractionation regimens to carefully
selected groups of women with early breast cancer is equivalent in
terms of local control, breast appearance, survival and late radiation
breast toxicity, with associated improvements in some cosmetic
parameters (telangiectasia and breast oedema).
Overall completeness and applicability of
evidence
Participants
These results are mostly applicable to women with small to
medium breasts, aged greater than 50 years, with node negative
tumours less than 3 cm in size, with negative pathological margins.
Sixty-eight percent (5332/7824) of the women enrolled in the
nine studies were node negative (see Table 4) and 100% of the
women studied in this review had negative pathological margins
(not stated in Saha 2009 orOwen 2006a). T3 tumours (larger than
5 cm) account for 9% (724/7513) of the total number of women
studied. Most women studied in this review had small to medium
breasts (83%; 4859/5845, where breast size was reported).
Treatment and follow-up
The length of follow-up was not adequate to detect differences in
breast cancer mortality (not apparent before 15 years’ follow-up)
(EBCTCG 2011). If, however, there are truly no differences in
local recurrence or late toxicity (e.g. cardiac morbidity) one would
not expect to see differences in mortality. We did not see an in-
crease in either late RT skin toxicity (Analysis 1.6) or late subcu-
taneous toxicity (Analysis 1.7) at either five or 10 years’ follow-
up. We found no differences in breast shrinkage (Analysis 1.10),
rib fractures (Analysis 1.12) or ischaemic heart disease (Analysis
1.11) with longer follow-up. With respect to radiation therapy-
induced ischaemic heart disease (IHD), there is an excess risk of
IHD after radiation therapy which is proportional to the mean
heart dose (MHD) received. This increased risk is apparent at four
years and persists for many years (Darby 2013). It is axiomatic that
the reduction in MHD dose received may be of clinical benefit,
reducing the risk of IHD for women with left-sided breast cancer
treated with radiation therapy. The use of specialised radiother-
apy techniques, such as deep inspiration breath hold (DIBH) can
dramatically reduce MHD (Eldrege-Hindy 2015; Sixtel 2001).
It is possible that the reduction in acute radiotherapy toxicity seen
when altered fraction size is used (Analysis 1.5), resulted in a re-
duction in consequential late radiation-induced effects, such as
telangiectasia (Analysis 1.8) and breast oedema (Analysis 1.9).
Radiation dose
In total, 442 local recurrences were reported in 8050 women. Us-
ing an alpha/beta ratio of four for breast tumour cells (Fowler
1989; Steel 1987; Williams 1985) allows conversion of radiation
doses to EQD2 (Maciejewski 1986; Withers 1983). When the al-
tered fraction size regimen radiation doses are converted to EQD2
(see Table 4), it is clear that some of the altered regimens (39 Gy in
13 fractions, 42.5 Gy in 13 fractions, 41.6 Gy in 13 fractions and
40 Gy in 15 fractions) (Owen 2006a; START A 2008; START B
2008; Whelan 2002b) have lower EQD2 than the conventional
50 Gy in 25 fractions. Subgroup analysis by dose (less than 50 Gy
versus 50 Gy) did not reveal any differences: Chi2 = 0.27, I2 =
0%, P = 0.06. Bartelink 2008 showed that all women irrespective
of age showed improved local control with addition of a 16 Gy
boost to conventionally fractionated radiotherapy. The reason for
the lack of a difference in local control with lower EQD2 used in
the altered fraction size trials is uncertain. Possible reasons include
the impact of the boost used in 44% of women treated (see Table
8), but it may reflect the effect of the use of more and better sys-
temic therapy which also improves local control. For Shaitelman
2015, START A 2008 and START B 2008, the use of a boost
was roughly equally divided between the treatment arms. While
boosts are associated with decreased local recurrence, they are also
associated with poorer cosmesis (Bartelink 2007).
Cost, peoples’ preference and quality of life
It has not been possible at this time to answer questions of cost and
patient preferences within this review. There was significantly less
acute radiation toxicity in the altered arm and one could reason-
ably expect that shorter regimens are more readily tolerated and,
therefore, would enhance the treatment experience for women.
The use of altered fraction size was associated with less fatigue
(both participant- and physician-reported) and there was no effect
on patient-reported quality-of-life measures at six months, sug-
gesting there was no detrimental effect on quality of life.
A detailed assessment of quality of life is planned for a subset of
women enrolled in START A 2008 and START B 2008, which
may provide more information. These data have not yet been
reported by study arm, sowe couldnot include them in this version
of the review. Little is known about patient preferences in this
setting but as rural women have consistently been shown to have
more mastectomies in comparison with women who live in bigger
centres (Nattinger 2001; Schroen2005) it may be that they choose
mastectomy to reduce their time away from home (assuming they
are offered conservative treatment as frequently as women in urban
areas).
Adjuvant therapies
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We do not have information about combining other therapies
(for example, trastuzumab) with these fractionation regimens, al-
though observational data suggest it to be a safe practice with con-
ventionally fractionated radiation therapy (Romond 2005).
Optimum fraction size
The optimum ’dose’ of altered fraction size remains unknown. In
FAST 2011; Owen 2006a and START A 2008, two novel altered
fraction size schedules were tested, however we were not able to
analyse them separately to see if one was superior to the other.
We did not find a difference in LR-FS when we analysed by dose
less than 50 Gy versus 50 Gy or more in the experimental arm
(test for subgroup difference I2 = 0%, P = 0.58). In addition, new
techniques (such as accelerated partial breast irradiation) shorten
treatment time evenmore by using larger fraction sizes to a smaller
volume of breast tissue. These techniques are the subject of a num-
ber of ongoing trials.
Technological innovations
New technology, for example, intensity modulated radiation ther-
apy (IMRT), which uses multiple radiation beams in order to
make treatment highly conformal (thus reducing dose to normal
structures) and improve dose distribution has been shown to de-
crease acute radiotherapy toxicity (Donovan 2007) and improve
cosmesis (Pignol 2008).
Quality of the evidence
We studied 8228 women enrolled in nine trials. There is now a
large body of high quality evidence allowing robust conclusions.
Local recurrence-free survival
For the outcome of LR-FS we did not downgrade for risk of bias,
indirectness, inconsistency (I2 = 0%, P = 0.61), imprecision (more
than 300 events (360), optimum information size (OIS) was met
and 95%confidence intervals (CIs) excluded clinicallymeaningful
benefits or harms) or publication bias. The GRADE quality of
evidence was therefore judged to be ’high’.
Cosmesis
For the outcome of cosmesis we downgraded for risk of bias, be-
cause one study (Whelan 2002b) did not blind outcome assessors
for subjective outcomes, this study contributed 1220/2103 (60%)
of the data for cosmetic outcome. We did not downgrade for indi-
rectness, inconsistency (I2 = 15% , P = 0.32), imprecision (more
than 300 events (687), OIS met and 95% CIs included one, and
excluded clinically meaningful benefits or harms) or publication
bias. The GRADE quality of evidence was therefore judged to be
’high’.
Toxicity - late subcutaneous fibrosis
For late subcutaneous fibrosis we did not downgrade for risk of
bias, as only 5%of eventswere contributed froma study at high risk
of bias for lack of blinding.We did not downgrade for indirectness,
or inconsistency (I2 = 0, P = 0.4). We did not downgrade for
imprecision (because there were more than 300 events (975), OIS
was met and CIs included one, but excluded clinically meaningful
benefits or harms) or publication bias. The GRADE quality of
evidence was therefore judged to be ’high’.
Overall survival
For overall survival we did not downgrade for risk of bias, indirect-
ness or inconsistency (I2 = 19, P = 0.29). We did not downgrade
for imprecision (more than 300 events (991), OIS was met and
the CIs included one, and excluded clinically meaningful benefits
or harms) or publication bias. The GRADE quality of evidence
was therefore judged to be ’high’.
Breast cancer-specific survival
For breast cancer-specific survival we did not downgrade for risk
of bias (12% of events came from a study deemed at high risk of
bias because of a lack of blinding), indirectness, or inconsistency
(I2 = 0%, P = 0.42). We did not downgrade for imprecision (be-
cause there were more than 300 events (673), OIS was met and
CIs included one, but excluded clinically meaningful benefits or
harms) or publication bias. The GRADE quality of evidence was
therefore judged to be ’high’.
Relapse-free survival
For relapse-free survival, we did not downgrade for risk of bias or
indirectness, but did downgrade for inconsistency (I2 = 74%, P =
0.05). We did not downgrade for imprecision (because there were
more than 300 events (673), OIS was met and CIs included one,
but excluded clinically meaningful benefits or harms) or publica-
tion bias. The GRADE quality of evidence was therefore judged
to be ’moderate’.
Mastectomy rate
We found no data with respect to this outcome.
Potential biases in the review process
We
believe we have identified the relevant studies, and we have iden-
tified five ongoing studies (see NCT00459628; NCT00909818;
NCT01266642; NCT01349322; NCT01413269). The ongoing
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studies will include women treated with moremodern chemother-
apy agents and hormonal manipulation.
There are limitations related to assessment of subjective outcomes,
such as cosmesis and breast induration, but this was well-per-
formed using standardised tools by trained observers in Owen
2006a andWhelan 2002b, with blinding of the outcome assessors
to the treatment allocation in FAST 2011; Owen 2006a STARTA
2008; START B 2008; Shaitelman 2015 Taher 2004 andWhelan
2002b.
Agreements and disagreements with other
studies or reviews
Published guidelines with respect to this question are as follows.
NICE guidelines state: “Use external beam radiotherapy giving 40
Gy in 15 fractions as standard practice for patients with early inva-
sive breast cancer after breast conserving surgery or mastectomy”.
NCCN guidelines state: “The breast should receive 45-50 Gy in
23 to 25 fractions or 40 to 42.5 Gy in 15 to 16 fractions (short
course is preferred)”.
American Society for Therapeutic Radiation Oncology (ASTRO)
guidelines state: “Evidence from randomized clinical trials has
demonstrated that hypo-fractionated- whole breast irradiation
(HF-WBI) and conventionally fractionated (CF)-WBI are equally
effective for in-breast tumour control and comparable in long term
side effects for patients meeting all the criteria listed (see Table 10).
The task force was unable to reach agreement as to the equivalence
of HFWBI to CF-WBI for patients who do not satisfy all these
criteria, and thus, we could not make a recommendation either
for or against the use of HF-WBI in such patients.” (Smith 2011).
We found one systematic review of hypofractionation for breast
and prostate cancer (Ray 2015). The authors searched Web of
Science, PubMed, Google Scholar and ICTRP (search date not
reported) as well as trawling reference lists. They conclude: “Hy-
pofractionation in breast cancer treatment is now the standard
protocol in the UK. ” (Ray 2015).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In selected women with early breast cancer (with negative mar-
gins and size 3 cm or less, with small to medium sized breasts),
shortened fractionation regimens are not detrimental for cancer-
related outcomes (no clinically meaningful difference with the use
of altered fraction size. Clinically meaningful benefits or harms ex-
cluded for local recurrence-free survival, overall survival, relapse-
free survival and breast cancer-specific survival) and altered frac-
tion size may be associated with a reduction in late radiation ther-
apy toxicity. There still remains uncertainty about the effect of
altered fraction size on ischaemic heart disease, although new ra-
diation techniques, which avoid treating the heart, mean this of
less importance.
Implications for research
There are a number of questions still unanswered with respect to
costs and quality of life that relate to the use of altered fraction
size in the treatment of early breast cancer for women undergoing
breast cancer surgery. These questions are likely to be answered by
both ongoing studies and future publications of completed studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
FAST 2011
Methods Randomised controlled trial, multi-centred, set in UK
Participants N = 729/915 women ≥ 50 years, invasive BC, treated with BCS, tumour size < 3 cm,
negative margins, negative axilla (surgically staged). Excluded: RNI, MRM, boost and
neoadjuvant or adjuvant chemotherapy
Interventions Altered fraction size: N = 613; 30 Gy/5 # or 28.5 Gy/5 #
Conventional RT: N = 302; 50 Gy/25 #
Outcomes Primary outcome: photographic change in beast appearance
Secondary outcome: clinically assessed RT-induced changes in breast, local control
Notes Median follow-up 37.3 months
Funding: NHS, Cancer Research UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “treatment allocation used com-
puter-generated random permuted blocks”
page 94, paragraph 3
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed by
telephone or facsimile” Page 94, paragraph
3
Blinding (performance bias and detection
bias)
Subjective outcomes
Low risk Quote: “All photographs were scored by
three observers blinded to patient identity
and treatment allocation”, page 94, para-
graph 8
Blinding (performance bias and detection
bias)
Objective outcomes
Low risk Quote: “Treatment allocation could not be
blinded due to the nature of the interven-
tion” page 94, paragraph 3
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk Attrition was clearly detailed, by arm, with
reasons given; page 96, Figure 1
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Attrition was clearly detailed, by arm, with
reasons given; page 96, Figure 1
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FAST 2011 (Continued)
Selective reporting (reporting bias) Unclear risk We did not have access to the study proto-
col, so judged this domain to be at unclear
risk of bias
Other bias Low risk We found no other sources of bias
Owen 2006a
Methods Randomised, multi-centre setting: tertiary cancer centres, set in UK
Participants 1410 British women with operable (T1-3N0-1MO) invasive breast cancer requiring
radiotherapy. 1138 women had small or medium breasts (from photographs at baseline)
. Median follow-up 9.7 years (range 7.8 to 11.8) Mean age of women: 54.5 years
Interventions Experimental arm (n = 474): 39 Gy in 13 fractions, or 42.9 Gy in 13 fractions (N =
466) over 5 weeks
Control arm (N = 470): 50 Gy in 25 fractions over 5 weeks
Outcomes Primary outcome: late change in breast appearance (scored from photos)
Secondary endpoints: palpable breast induration and ipsilateral breast recurrence.
Women reviewed 3-monthly to 36 months, 6-monthly to 60 months, then annually.
Annual physician toxicity review. Photographs annually to 60 months, then at 10 years
in all evaluable participants
Notes Photos: frontal photos taken after surgery before RT, then annually to 5 years and at 10
years under standard conditions. Photos scored by 3 observers
In total, 196/1410 women received chemotherapy and 1074/1410 received tamoxifen
(numbers not given by study arm)
Funding: Marks and Spencer PLC and Cancer Research UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “were randomised” (Abstract). Not
adequately described to be sure it was truly
randomised
Allocation concealment (selection bias) Low risk Quote: “randomisation achieved by a tele-
phone call to the Clinical trials and Statis-
tics Unit at the Institute of Cancer Re-
search, Sutton” (Para 3, page 10)
Quote: “Randomisation was done by tele-
phone at the Clinical trials and Statistics
Unit (ICR-CTSU) at the Institute of Can-
cer Research, Sutton by the clinician (early
in the trial), who recorded it in the patient’s
notes and did not have any further role
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Owen 2006a (Continued)
in the randomisation process, and then by
a research nurse. Although randomisation
was not blinded” (Paragraph 2, page 3)
Blinding (performance bias and detection
bias)
Subjective outcomes
Low risk Participant: not mentioned, unlikely to be
a problem for nurse- or clinician-assessed
outcomes
Personnel: not mentioned, probably not
done
Assessors: photographic assessors blinded
to treatment arm. Quote: “Assessments
of the change in breast appearance were
blinded” (Paragraph 3, page 2). Clinical as-
sessments were not blinded (although done
by many people, which may potentially re-
duce bias)
Blinding (performance bias and detection
bias)
Objective outcomes
Unclear risk Participant: not mentioned, probably not
done, unlikely to be a source of bias
Personnel: not mentioned, probably not
done
Assessors: not mentioned, probably not
done
Although time points for clinical examina-
tions were pre-specified, there is no men-
tion of the timing of mammograms
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk Cosmetic outcome, late radiation toxicity
and quality of life: 1202/1410 women had
photos at both baseline and at a later time
point. Quote: “reasons for non-availabil-
ity explored, and no evidence was observed
that this was associated with either the frac-
tionation schedule or to the probability of
experiencing future normal tissue event or
local relapse.” (These data not reported)
Reasons for attrition not detailed, a po-
tential source of bias, but the number of
women without a photo comprised < 15%
of the cohort, so judged at low risk of bias
The first 806/1410 women had prospec-
tively collected physician assessments (in-
cluding normal tissue effects) for ten years.
It is not clear why these women were cho-
sen and the others excluded from the sam-
ple
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Owen 2006a (Continued)
Incomplete outcome data (attrition bias)
Objective outcomes
Low risk Attrition: 42.9 Gy in 13 fractions; 8 lost to
follow-up, 4 moved, 4 unable to attend
39 Gy in 13 fractions; 2 lost to follow-up,
1 emigrated, 1 unable to be traced
50 Gy in 25 fractions; 8 lost to follow-up,
7 moved (2 emigrated), 1 did not attend
appointments and was then discharged
Selective reporting (reporting bias) Unclear risk Outcomes specified in methods/protocol:
late change in breast appearance (scored
fromphotographs), palpable breast indura-
tion (fibrosis), ipsilateral tumour recur-
rence
Outcomes reported in paper: late change
in breast appearance (scored from pho-
tographs), clinical assessment of cosme-
sis, breast shrinkage, distortion, oedema,
induration, telangiectasia, arm oedema,
shoulder stiffness, local recurrence, distant
relapse, contralateral breast cancer
Other bias Unclear risk Premature reporting for primary endpoint
(subjective). Quote: “minimum 5 year
follow-up”. Study stopped early because
START trials commenced
Patni 2012
Methods RCT
Participants N = 40 women with early breast cancer
Interventions Experimental arm: 40 Gy/15 fractions + electron or brachytherapy boost
Control arm: 50 Gy/25 fractions + electron or brachytherapy boost
Outcomes Acute RT toxicity assessed at 7-10 days after RT (dermatitis, breast pain, breast oedema,
heat sensations)
Chronic toxicity assessed at 6 months
Locoregional control and disease-free survival
Notes CTCAE version 3.0 used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote:“randomly assigned” no further details, so judged at un-
clear risk of bias
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Patni 2012 (Continued)
Allocation concealment (selection bias) Unclear risk No description, so judged at unclear risk of bias
Blinding (performance bias and detection
bias)
Subjective outcomes
Unclear risk No details described, probably not done
Blinding (performance bias and detection
bias)
Objective outcomes
Unclear risk No details described, probably not done
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk No details given
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk No details given
Selective reporting (reporting bias) Unclear risk No information, study reported in abstract form
Other bias Unclear risk Nil observed
Saha 2009
Methods Randomised, single institution pilot study, country: India
Participants N = 131 women with early breast cancer, treated with mastectomy (N = 84, BCS = 47)
Interventions Experimental arm: N = 69 (24/69 had BCS) 30 Gy/5 #
Control arm: N = 62 (23/62 had BCS) 50 Gy/25 #
Outcomes Locoregional recurrences, late toxicity (scored using LENT-SOMA) and cosmetic out-
come (evaluated by a panel using four-point scale)
Notes All women received FAC (6 cycles)
Median follow-up: 42 months
Sequential boost, using HDR given in 41/47 BCS participants
Funding: no details given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “randomised”. No details given, so
graded as unclear
Allocation concealment (selection bias) Unclear risk No details given so graded as unclear
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Saha 2009 (Continued)
Blinding (performance bias and detection
bias)
Subjective outcomes
Unclear risk No details given so graded as unclear
Blinding (performance bias and detection
bias)
Objective outcomes
Unclear risk No details given so graded as unclear
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk No details given so graded as unclear
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk No details given so graded as unclear
Selective reporting (reporting bias) Unclear risk As we only had an abstract, this domain
was graded as unclear
Other bias Low risk We found no other sources of bias
Shaitelman 2015
Methods RCT
Participants N = 287 women with Stage Tis, 1-2N0-1aM0 BC breast cancer treated with BCS, with
negative margins
Interventions Experimental arm: N = 138; 42.5 Gy in 16 fractions + 10-12.5 Gy boost in 4-5 fractions
Control arm: N = 149; 50 Gy in 25 fractions + 10-14 Gy boost in 5-7 fractions
Outcomes Primary: Participant-reported cosmesis at three years
Secondary: Dr-reported cosmesis, acute toxicity, patient-reported quality of life, in breast
tumour recurrence (IBTR)
Notes Quality of life assessed using FACT-B
Acute toxicity assessed by physicians RTOG CTCAE
Fatigue assessed by both participants and clinicians
Dose homogeneity required (cold use wedges, 3DCRTor IMRT) to achievemax < 108%
of prescribed RT dose
Respiratory gating allowed
Funding: no details supplied
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote:“were randomly allocated”, page E2, paragraph 7
Quote:“The Popcock-Simon randomisationmethodswas used”,
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Shaitelman 2015 (Continued)
page E2, paragraph 7
Allocation concealment (selection bias) Unclear risk Quote:“were randomly assigned” Abstract, paragraph 1 No de-
tails given, so judged to be at unclear risk of bias
Blinding (performance bias and detection
bias)
Subjective outcomes
Low risk Quote: “Acute toxicity...as assessed by physicians”, no mention
of blinding, therefore judged as unclear
Cosmetic outcome was physician-reported, quote: “postopera-
tive physician reported cosmetic assessment”, E2, paragraph 7
and no mention is made of blinding, but the protocol makes
it clear the physician panel is blinded to treatment arm, which
makes this domain at low risk of bias.
Quote: “patient-reported QOL” Page E2, paragraph 9, which
makes this at low risk of bias. We deemed this to be at low risk
of bias, these results were not presented in this report. The use
of a pre-specified toxicity reporting scale may have reduced the
risk of bias even though it was assessed in an unblinded fashion
Blinding (performance bias and detection
bias)
Objective outcomes
Unclear risk No objective outcomes reported, so judged at unclear risk of bias
Incomplete outcome data (attrition bias)
Subjective outcomes
Low risk Attrition:
Experimental 0 (acute RT toxicity), 7 (late RT toxicity), 20
(QOL at 6 months)
Control: 0 (acute RT toxicity), 9 (late RT toxicity) 0 QOL at
6 months. SInce attrition was reported clearly by study arm, we
deemed this to be at low risk of bias
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk No objective outcomes reported, but this is a first report, focus-
ing on subjective outcomes, we judged this to be at unclear risk
of bias
Selective reporting (reporting bias) Unclear risk This report of the study does not include physician reported
cosmetic outcomes, but thesewill likely be reported in the future,
we judged this to be at unclear risk of bias
Other bias Low risk We found no other sources of bias
START A 2008
Methods Randomised, multi-centre setting: tertiary cancer centres
Participants 2236 British women with operable (T1-3N0-1M0) invasive breast cancer requiring
radiotherapy. 1071/1250 women (with photographs available at baseline) had small or
medium breasts. Median follow-up 9.3 years. Mean age 57.2 years
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START A 2008 (Continued)
Interventions Experimental arm (N = 750): 41.6 Gy in 13 fractions or 39 Gy in 13 fractions (N =
737) over 5 weeks
Control arm (N = 749): 50 Gy in 25 fractions over 5 weeks
Outcomes Primary outcome: loco-regional relapse, normal tissue effects and quality of life
Secondary outcomes: disease-free survival, overall survival, second primaries, health eco-
nomics consequences (not specified) and toxicity. Women reviewed annually for loco-
regional relapse and normal tissue effects
Notes Normal tissue effects assessed by photos, patient and doctor assessments Photos at base-
line, 2 and 5 years (blinded assessment)
Funding: Cancer Research UK, UK Medical Research Council, UK Department of
Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned” (Abstract)
. Quote: “computer generated and not
blinded” (Abstract). Quote: “START A pa-
tients were randomised” (Para 3, page 3).
Probably done
Allocation concealment (selection bias) Low risk Quote: “Randomisation was arranged via
telephone at the Clinical Trials and Statis-
tics Unit at the Institute of Cancer Re-
search (ICR-CTSU), Sutton, UK, where
the patient details were recorded and treat-
ment allocated. Randomisation was not
blinded. Computer-generated permuted
blocks were used as a method of allocation”
(Para 4, page 3)
Provided those undertaking recruitment
are not aware that permuted blocks are be-
ing used, or the block size, then this should
not distort the recruitment
Blinding (performance bias and detection
bias)
Subjective outcomes
Low risk Participant: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: Quote: “Changes in breast ap-
pearance (photographic) were scored by
three observers blinded to patient identity,
treatment allocation and year of follow up”
(Para 3, page 4). Probably done and this is
most important for assessment of this sub-
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jective primary outcome
Blinding (performance bias and detection
bias)
Objective outcomes
Unclear risk Participant: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: not mentioned, probably not
done. Although time points for clinical ex-
aminations were pre-specified, there is no
mention of the timing of mammograms,
which may be a source of bias
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Cosmetic outcome, late radiation toxicity
and quality of life: Quote: “1129/2236 en-
rolled in quality of life study”
It is not clear how the participants enrolled
in the quality-of-life study were selected
1306/2236
enrolled in photographic study: assessed in
1055 participants with both a baseline and
a follow-up photograph
Quote: “There were no associations be-
tween score for change in breast appearance
(photographic) at two years or patient de-
mographic or treatment characteristics and
whether or not the patient had a five-year
assessment (data not shown).”
It is not clear why not all participants were
enrolled in the photographic study
Incomplete outcome data (attrition bias)
Objective outcomes
Low risk Attrition described clearly: Quote: “41.6
Gy in 13 fractions; 2 with baseline data
only, 1 moved, 1 unknown, 39 Gy in 13
fractions; 2 with baseline data only, 2 with-
drew consent to follow up after randomisa-
tion, 50 Gy in 25 fractions; 5 with baseline
data only, 3 withdrew consent to follow up
after randomisation, 2 moved”
Selective reporting (reporting bias) Unclear risk Outcomes specified in methods/protocol:
local-regional tumour relapse, late nor-
mal tissue effects (photographic change in
breast appearance). Quality of life, dis-
ease-free survival, overall survival, second
primary cancers, health economic conse-
quences, ischaemic heart disease, symp-
tomatic rib fracture, symptomatic lung fi-
brosis, brachial plexopathy
Outcomes reported in paper: local-regional
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tumour relapse, distant relapse, disease-free
survival, overall survival, second primary
cancers, ischaemic heart disease, symp-
tomatic rib fracture, symptomatic lung
fibrosis, brachial plexopathy, disease-free
survival, overall survival, second primary
cancers, ischaemic heart disease, symp-
tomatic rib fracture, symptomatic lung fi-
brosis, brachial plexopathy
“Quality of life outcomeswill be the subject
of another paper”. Health economic con-
sequences not reported
Other bias Unclear risk Quote: “Not all patients had photographs
available at both 2 and 5 years, for reasons
including the 5-year assessment not being
yet due at the time of scoring and analysis.
..” This may represent early reporting
START B 2008
Methods Randomised, multi-centre setting: tertiary cancer centres
Participants 2215 British women with operable (T1-3N0-1M0) invasive breast cancer requiring
radiotherapy. 858/1036women treatedwith breast conserving surgery (with photographs
available at baseline) had small or medium-sized breasts. Median follow-up 9.7 years.
Mean age 57.4 years
Interventions Experimental arm (N = 1110): 40 Gy in 15 fractions over 3 weeks
Control arm (N = 1105): 50 Gy in 25 fractions over 5 weeks
Outcomes Primary outcome: loco-regional relapse, normal tissue effects and quality of life
Secondary outcomes: disease-free survival, overall survival, second primaries, health eco-
nomics consequences (not specified) and toxicity. Women reviewed annually for loco-
regional relapse and normal tissue effects
Notes Normal tissue effects assessed by photos, patient and doctor assessments Photos at base-
line, 2 and 5 years (blinded assessment)
Funding: Cancer Research UK, UK Medical Research Council, UK Department of
Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned” (Abstract)
. Quote: “computer generated and not
blinded” (Abstract). Quote: “START B pa-
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tients were randomised” (Para 2, page 2).
Probably done
Allocation concealment (selection bias) Low risk Quote: “Randomisation was arranged via
telephone at the Clinical Trials and Statis-
tics Unit at the Institute of Cancer Re-
search (ICR-CTSU), Sutton, UK, where
the patient details were recorded and treat-
ment allocated. Randomisation was not
blinded. Computer-generated permuted
blocks were used as a method of allocation”
(Para 2, page 2)
Provided those undertaking recruitment
are not aware that permuted blocks are be-
ing used, or the block size, then this should
not distort the recruitment
Blinding (performance bias and detection
bias)
Subjective outcomes
Low risk Participant: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: Quote: “Changes in breast ap-
pearance (photographic) were scored by
three observers blinded to patient identity,
treatment allocation and year of follow up”
(Para 2, page 3). Probably done and this is
most important for assessment of this sub-
jective primary outcome
Blinding (performance bias and detection
bias)
Objective outcomes
Unclear risk Participant: not mentioned, probably not
done; unlikely to have impact
Personnel: not mentioned, probably not
done; unlikely to have impact
Assessors: not mentioned, probably not
done. Although time points for clinical ex-
aminations were pre-specified, there is no
mention of the timing of mammograms,
which may be a source of bias
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Cosmetic outcome, late radiation toxicity,
quality of life
1094/2215 enrolled in photographic study
Quote: “There were no associations be-
tween score for change in breast appearance
(photographic) at two years or patient de-
mographic or treatment characteristics and
whether or not the patient had a five-year
assessment (data not shown).”
It is not clear why not all participants were
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enrolled in photographic study
1079/2215 enrolled in quality-of-life study
It is not clear how the women enrolled in
the quality-of-life study were selected
Incomplete outcome data (attrition bias)
Objective outcomes
Low risk Attrition: 40 Gy in 15 fractions arm; 10
with baseline data only, 3 ineligible, 7 with-
drew consent to follow-up after randomi-
sation
50 Gy in 25 fractions; 9 with baseline data
only, 5 withdrew consent to follow-up after
randomisation, 2 moved, 2 unknown (Fig
1)
Unlikely to introduce bias in objective out-
comes
Selective reporting (reporting bias) Unclear risk Outcomes specified in methods/protocol:
local-regional tumour relapse, late nor-
mal tissue effects (breast, arm and shoul-
der) assessed by photographic, self-reported
and doctor assessed. Quality of life, dis-
ease-free survival, overall survival, second
primary cancers, health economic conse-
quences, ischaemic heart disease, symp-
tomatic rib fracture, symptomatic lung fi-
brosis, brachial plexopathy
Outcomes reported in paper: local-regional
tumour relapse, distant relapse, disease-
free survival, overall survival, change in
breast appearance (photographic), patient
self-assessment of breast, ischaemic heart
disease, symptomatic rib fracture, symp-
tomatic lung fibrosis, brachial plexopa-
thy, acute radiation therapy reactions, con-
tralateral breast cancers, second primary
cancers. Health economic consequences
have not been reported
Other bias Unclear risk Version of “early stopping” or early report-
ing, (median follow-up 6.0 years). 1094 en-
rolled in photographic study, but the out-
come assessed in 923 women (with both
photograph at baseline and either 2 or 5
years follow-up)
It is possible that the numbers of women
with 5 years’ follow-up is small, but detail
is not given
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Taher 2004
Methods RCT, setting Egypt
Participants N = 30 women > 65 years, with T1-2N0M0 treated with BCS, negative margins,
10 nodes removed, with separation < 25 cm,
Interventions Experimental arm: 42.5 Gy/16 fractions plus
Control arm: 50 Gy/25 fractions plus 10 Gy/5 fraction boost
Outcomes Acute skin toxicity
Late cosmetic outcome
Notes Chemotherapy (20/30) and hormonal therapy given (but not detailed by arm)
Funding: not stated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote: “a controlled randomized, open (with allocation con-
cealment using closed-envelope method)” Page 179, paragraph
3. Inadequate detail given, so deemed at unclear risk of bias
Allocation concealment (selection bias) Unclear risk Quote: “a controlled randomized, open (with allocation con-
cealment using closed-envelope method)” Page 179, paragraph
3. Inadequate detail given, so deemed at unclear risk of bias. The
use of closed envelopes can lead to high risk of bias, so more
details required to make a judgement
Blinding (performance bias and detection
bias)
Subjective outcomes
Low risk Quote: ’The RTOG scoring system for radiation reactions were
used to score radiation toxicity. The cosmetic outcome was as-
sessed at 6, 12 and 24 months. The second author was the one
to score cosmesis blinded to the treatment arm’, page 180, para-
graph 2. Although it is not stated that the assessor for acute tox-
icity was blinded, the assessor for cosmesis was, so we deemed
this category at low risk of bias
Blinding (performance bias and detection
bias)
Objective outcomes
Low risk Quote: “a controlled randomized, open” Page 179, paragraph 3.
Not blinded, which would have been difficult, given the nature
of the intervention, deemed at low risk of bias
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Not mentioned therefore judged at unclear risk of bias
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Not mentioned, therefore judged to be at unclear risk of bias
Selective reporting (reporting bias) Unclear risk We did not have access to the protocol, so judged this domain
to be at unclear risk of bias
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Other bias Unclear risk There was inadequate detail to allow judgement
Whelan 2002b
Methods Randomised, multi-centred, setting: tertiary institutions
Participants 1234 Canadian women with invasive breast cancer (< 5 cm, i.e. no T3/T4 lesions,
negative margins and node negative) treated with lumpectomy. Exclusions: those with
multi-centric disease, large breasts (separation > 25 cm) and those with bilateral breast
cancer. Median follow-up 12 years. Approximately 75% of the women were aged over
50 years
Interventions Experimental arm (N = 622): radiation dose to breast alone; 42.5 Gy in 16 fractions
(dose per fraction 2.65 Gy, BED = 70.65)
Control arm (N = 612): radiation dose 50 Gy in 25 fractions (dose per fraction 2.0 Gy,
BED = 75)
Outcomes Primary outcome: local recurrence of invasive breast cancer in treated breast
Secondary outcomes: distant recurrence of invasive breast cancer, death, breast cosmesis
and late radiation toxicity. Cosmesis assessed using EORTC Cosmetic Rating System
(by trained nurse). Global cosmetic outcome assessed using 4-point scale.
Late radiation toxicity assessed by trained nurse using RTOG/EORTC late radiation
morbidity scale
Notes Concurrent interventions were evenly divided between the 2 arms: 254 women in the
experimental arm received tamoxifen and 251 in the control arm, 70 women in the
experimental arm received chemotherapy and 66 in the control arm. Moderate risk of
bias
Funding: National Cancer Institue Canada and Ontario Clinical Oncology Group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “randomly assigned” (Abstract)
Quote: “computer-generated central ran-
domisation schedule within strata defined
by age (< 50 years or ≥ 50 years), tumour
size (≤ 2 cm or > 2 cm), adjuvant systemic
therapy (tamoxifen, any chemotherapy or
on therapy) and centre” (Para 3, page 4)
It sounds as if it was truly randomised
Allocation concealment (selection bias) Unclear risk Quote: “computer-generated central ran-
domisation schedule within strata defined
by age (< 50 years or ≥ 50 years), tumour
size (≤ 2 cm or > 2 cm), adjuvant systemic
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therapy (tamoxifen, any chemotherapy or
on therapy) and centre” (Para 3, page 4)
It is not explicitly stated that the randomi-
sation process was concealed, although it
was central
Blinding (performance bias and detection
bias)
Subjective outcomes
High risk Participant: not mentioned, but the par-
ticipant cannot have been blinded, as they
would know how many fractions of RT
they received. This may affect how they
report the subjective outcomes, although
they were not participant-assessed
Personnel: not mentioned, probably not
done
Assessors: not mentioned (unlikely, given
the lack of blinding in other personnel)
but likely to introduce bias, particularly for
subjective outcomes e.g. cosmesis
Blinding (performance bias and detection
bias)
Objective outcomes
Low risk Participant: not mentioned, but the par-
ticipant cannot have been blinded, as they
would know how many fractions of RT
they received. Not possible to blind par-
ticipant, but unlikely to introduce bias in
objective outcomes, especially as interval
for mammography pre-specified. Quote:
“mammograms six monthly, then annu-
ally”
Personnel: not mentioned, probably not
done
Assessors: no commentmade, but as regular
mammograms performed, a lack of blind-
ing in outcome assessors could contribute
to lead time bias in the diagnosis of local
recurrence, but this would be unlikely to
be significant over a prolonged follow-up
period
Incomplete outcome data (attrition bias)
Subjective outcomes
Unclear risk Cosmetic outcome was assessed in 735/
1220 women; those who had follow-up to
5 years at the time of the initial trial report.
It may be that the reason others did not
have five years’ follow-up is because they
had not been in the trial long enough, but
it could also potentially be due to other
reasons, perhaps because of withdrawal or
non-attendance
Late radiation toxicity was assessed in 752/
1220 women at 5 years. It may be that not
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all women had 5 years’ follow-up, but this
is not made clear. The authors make the
point that most of the toxic effects of RT
are evident by 5 years’ follow-up
Incomplete outcome data (attrition bias)
Objective outcomes
Unclear risk Exclusions: 0
Although the number analysed equals the
number randomised, it seems unlikely that
all the participants would be available for
follow-up after a period of as long as 10
years. If there are missing data, there is
no information given about how they were
dealt with
Selective reporting (reporting bias) Unclear risk Outcomes specified in methods/protocol:
any local recurrence in treated breast, dis-
tant recurrence, death, breast cosmesis, late
RT toxicity. Cosmetic outcome: at 3 and 5
years. Late RT toxicity: at 3 and 5 years
Outcomes reported in paper: local recur-
rence-free survival, local recurrence rate,
disease-free survival, death, breast cosmesis,
late RT toxicity (both at 3 and 5 years), skin
toxicity, subcutaneous toxicity, rib fractures
and pneumonitis
Other bias Low risk No other sources of bias identified
BC: breast cancer
BCS: breast conserving surgery
BED: biological equivalent dose
Gy: Gray
M: metastases
MRM: modified radical mastectomy
N: lymph node
QoL: quality of life
RNI: regional nodal irradiation
RT: radiotherapy
T: tumour
#: fraction
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anon 1981 Surgery was wide local excision versus mastectomy
Baglan 2001 Did not examine external beam radiation
Baillet 1990 This is a preliminary report of an RCT, describing 230 of the 525 planned enrolment of women with breast
cancer, 50% were treated with mastectomy, 21% managed without surgery and 26%-30% had clinically
apparent nodes at baseline, 17% had inflammatory breast cancer. This population was ineligible for inclusion
in our review
Bates 1975 Surgery was modified radical mastectomy
Bates 1988 Surgery was modified radical mastectomy
Brinkley 1984 Surgery was modified radical mastectomy
Bruce 1971 Surgery was modified radical mastectomy versus simple mastectomy
Dvivedi 1978 Surgery was modified radical mastectomy and regional radiation therapy was examined
FAST-forward 2014 Control arm is 40 Gy/15 fractions (> 2 Gy per fraction)
Formenti 2002 Partial breast radiation therapy was examined
Goel 2000 Surgery was modified radical mastectomy
Liljegren 1993 Intervention was radiation therapy in experimental arm only
NCT00793962 Not breast conservation
NCT01247233 Partial breast irradiation
Olivotto 1996 Intervention was +/- aspirin
Ptaszynski 1999 Examined boost versus no boost
Romestaing 1997 Examined boost versus no boost
Sanguineti 2001 Was a chemotherapy trial
Spooner 2012 Study of immediate versus delayed RT. RT randomised to 40 Gy/15 versus 50 Gy/25 fractions, but study
ineligible because RT volume included breast, SCF and axilla
UK-FAST 2009 Control arm not conventional radiotherapy
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Vermessen 2012 45/121 (37%) women had mastectomy, 37/121 (30%) with involved nodes were treated with regional nodal
radiotherapy and 42/121 (34%) received concurrent chemotherapy
Vrieling 2000 Examined boost versus no boost
Wallace 1993 Women were treated with regional nodal irradiation
Wallgren 1978 Investigates preoperative radiation therapy
Wang 2013 Surgery was mastectomy
RCT: randomised controlled trial
Characteristics of ongoing studies [ordered by study ID]
NCT00459628
Trial name or title Tomobreast
Methods RCT
Participants Ages eligible for study: 18 years and older
Genders eligible for study: female
Accepts healthy volunteers: no
Inclusion Criteria:
Informed consent
Histologically proven breast carcinoma
Stage I or II (T1-3N0 or T1-2N1 M0, AJCC/TNM 6th edition)
Surgery with clear margins
Pre-operative medical imaging (at least CT, MRI, and/or PET-scan)
Exclusion Criteria:
Prior breast or thoracic radiotherapy
Pregnancy or lactation
Fertile women without effective contraception
Psychiatric or addictive disorders
Interventions Experiental arm:
CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system (45 Gy/
15 #)
Conventional radiotherapy:
Radiation therapy delivered by conventional linear accelerator using matching fields (50 Gy/25 #)
Outcomes Primary outcome measures:
Change from baseline in pulmonary function and heart function tests
Assessment by pulmonary function tests and by heart echocardiography, compared with test values prior to
treatment
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Secondary outcome measures:
Local-regional recurrences
Local-regional recurrences are assessed at time intervals as per the institution’s standard practice for the clinical
surveillance of women
Starting date May 2007
Contact information Vincent Vinh-Hung, MD, PhD, Clinical Professor, Vrije Universiteit Brussel
Notes N = 118 Accrual May 2007-Dec 2016
NCT00909818
Trial name or title Hypofractionated versus standard fractionated whole breast irradiation to node-negative breast cancer
Methods Randomised controlled trial
Parallel assignment
Participants Participants: women 41 years old
Inclusion criteria: operated with breast concerning strategy for (i) invasive breast cancer, pT1-2, pN0-1 mi,
M0 OR (ii) carcinoma in situ of the breast, tissue 20 mm and/or van Nuys > 1 and/or margin < 10 mm
Interventions Arm 1: standard fractionated radiotherapy (active comparator)
50 Gy / 25 fractions, 2 Gy/fraction, 5 fractions per week
Arm 2: hypofractionated radiotherapy (experimental)
Hypofractionated radiotherapy 40 Gy/15 fractions
Outcomes Grade 2 or 3 fibrosis 3 years after radiotherapy
Any other late morbidity after adjuvant radiotherapy
Genetic risk profile for late morbidity
Recurrent/Survival
Starting date May 2009
Contact information Birgitte Offersen (bvo@oncology.dk)
Notes Anticipated end date: May 2022
NCT01266642
Trial name or title Randomized Trial of Hypofractionated Whole Breast Irradiation Versus Conventionally Fractionated Whole
Breast Irradiation for Ductal Carcinoma in Situ and Early Invasive Breast Cancer
Methods Randomised safety study
Participants Inclusion Criteria:
Pathologically confirmed ductal carcinoma in situ of the breast or early invasive breast cancer defined as
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pathologic stage Tis, T1, or T2, N0, N1mic, or N1a (pathologic staging of the axilla is required for all patients
with invasive disease but is not required for patients with DCIS only). (Upfront pathologic stage cannot be
assigned to patients treated with neoadjuvant chemotherapy. For such patients, the criteria for pathologic
stage shall be applied to the initial clinical stage)
Treatment with breast conserving surgery
Final surgical margins must be negative, defined as no evidence for ductal carcinoma in situ or invasive breast
cancer touching the inked surgical margin. If the invasive or in situ breast cancer approaches within less than
1 mm of the final surgical margin, then a re-excision is strongly encouraged. Lobular carcinoma in situ at the
final surgical margin will be disregarded.
Age 40 years or older. This age cutoff is justified because breast cancers in women under the age of 40 are
known to have a significantly higher risk of IBTR presumably due to underlying biologic differences
Female
Attending radiation oncologist declares intention to treat the whole breast only and that a third radiation field
to treat regional lymph nodes is not planned (radiation of the un-dissected level I/II axilla with high tangents
is allowed)
If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed
prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer
Patients must be enrolled on the trial within 12 weeks of the later of two dates: the final breast conserving
surgical procedure or administration of the last cycle of cytotoxic chemotherapy
Exclusion Criteria:
Pathologic or clinical evidence for a stage T3 or T4 breast cancer
Pathologic evidence for involvement of 4 or more axillary lymph nodes, or imaging evidence of involvement
of infraclavicular, supraclavicular, or internal mammary lymph nodes
Clinical or pathologic evidence for distant metastases
Any prior diagnosis of invasive or ductal carcinoma in situ breast cancer in either breast
Current diagnosis of bilateral breast cancer
History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could
potentially be overlap with the affected breast
Patients not fluent in English or Spanish. (The Informed Consent will be available in these two languages)
Patient is pregnant
Interventions Radiation: hypofractionated whole breast irradiation
42.56 Gy in 16 fractions delivered to the whole breast on consecutive treatment days
Boost of 10 Gy in 4 fractions or 12.5 Gy in 5 fractions delivered on consecutive days beginning on treatment
day following completion of whole breast irradiation
Radiation: conventionally fractionated whole breast irradiation
50 Gy in 25 fractions delivered to whole breast on consecutive treatment days
Boost of 10 Gy in 5 fractions or 14 Gy in 7 fractions delivered on consecutive treatment days, beginning on
treatment day following completion of whole breast irradiation
Outcomes Primary Outcome Measures:
Percentage of women with adverse cosmetic scores at 3 Years (time frame: 3 years) (designated as safety issue:
Yes)
Comparisonof patient-reported cosmetic outcomes usingBreast CancerTreatmentOutcomes Scale (BCTOS)
: 1) Hypofractionated whole breast irradiation (HF-WBI) versus 2) Conventionally fractionated whole breast
irradiation (CF-WBI). Number of women with adverse cosmetic scores at 3 years after completion of breast
conserving surgery, as determined by the patient-reported BCTOS where a score of 2.5 or more indicates an
adverse cosmetic outcome
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Starting date February 2011
Contact information Smith, B
Notes N = 288 Study commenced Feb 2011
NCT01349322
Trial name or title A phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus
standard whole breast irradiation plus sequential boost for early-stage breast cancer
Methods Phase II open label RCT
Participants Women aged 18-70
Disease characteristics:
1. Pathologically proven diagnosis of breast cancer resected by lumpectomy and whole-breast irradiation
(WBI) with boost without regional nodal irradiation planned
2. Must meet one of the following three criteria: pStage I or II breast cancer and at least one of the
following: age < 50 years or positive axillary nodes or lymphovascular space invasion (LVI) or at least 2 close
resection margins (> 0 mm to ≤ 2 mm) or one close resection margin and extensive in-situ component
(EIC) or focally positive resection margins or non-hormone-sensitive breast cancer (oestrogen and
progesterone receptor negative (ER- and PR-) or grade III histology or oncotype recurrence score > 25 or
pStage 0 breast cancer with nuclear grade 3 ductal carcinoma in situ (DCIS) and patient age < 50 years or
3. If multifocal breast cancer, then it must have been resected through a single lumpectomy incision with
negative margins
4. Breast-conserving surgery with margins defined as follows: negative margins defined as no tumour at
the resected specimen edge. Close resection margins > 0 mm to ≤ 2 mm as follows: 1 close resection margin
and EIC; 2 or more close resection margins; a focally positive resection margin
5. Allowable options for mandatory axillary staging include: sentinel node biopsy alone (if sentinel node
is negative, pN0, pN0[IHC-,+]); sentinel node biopsy alone, or followed by axillary node dissection, for
clinically node-negative patients as described below; microscopic sentinel node (SN) positive (pN1mic); 1
or 2 SNs positive (pN1) without extracapsular extension; negative SN biopsy after neoadjuvant
chemotherapy. Axillary node dissection is required following SN biopsy with a minimum total of 6 axillary
nodes if any of the following exist: for > 2 positive SN; any positive SN biopsy after neoadjuvant
chemotherapy; for clinically (by either imaging or examination) T3 disease; for extracapsular extension.
Axillary dissection alone (with a minimum of 6 axillary nodes)
6. CT-imaging of the ipsilateral breast within 28 days of study entry for the radiation therapy planning.
Must be able to delineate on CT scan the extent of the target lumpectomy cavity for boost (placement of
surgical clips to assist in treatment planning of the boost is strongly recommended)
7. No clinical evidence for distant metastases, based upon the following minimum diagnostic workup:
history/physical examination, including breast exam (inspection and palpation of the breasts) and
documentation of weight and Zubrod Performance Status of 0-2 within 28 days prior to study entry; a
mammogram of both right and left breast within only 1 time point of 90 days of the diagnostic biopsy
establishing the diagnosis
8. No prior invasive or in-situ carcinoma of the breast (prior LCIS is eligible)
9. No American Joint Committee on Cancer (AJCC) pathologic T4, N2 or N3, or M1 breast cancer
10. Must not have two or more breast cancers that are not resectable through a single lumpectomy incision
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11. Must not be DCIS and ≥ 50 years old
12. Must not be DCIS only (without an invasive component), nuclear grade 1 or 2 and < 50 years old
13. No suspicious unresected microcalcification, densities, or palpable abnormalities (in the ipsilateral or
contralateral breast) unless biopsied and found to be benign
14. No non-epithelial breast malignancies such as sarcoma or lymphoma
15. No Paget disease of the nipple
16. No male breast cancer
17. Breast implants allowed
Patient characteristics:
1. ANC ≥ 1,800/mm³
2. Platelet count ≥ 75,000/mm³
3. Haemoglobin ≥ 8.0 g/dL (transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable)
4. Negative urine or serum pregnancy test within 14 days of study entry
5. Women of childbearing potential must not be pregnant or nursing and willing to use medically
acceptable form of contraception during radiotherapy
6. No prior invasive non-breast malignancy (except non-melanomatous skin cancer or carcinoma in situ
of the cervix) unless disease free for a minimum of 5 years prior to study entry
7. No severely active co-morbidity, defined as follows: unstable angina and/or congestive heart failure
requiring hospitalisation within the last 6 months; transmural myocardial infarction within the past 6
months; acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;
chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalisation or
precluding study therapy within 30 days before registration; hepatic insufficiency resulting in clinical
jaundice and/or coagulation defects; note, however, that laboratory tests for liver function and coagulation
parameters are not required for entry into this protocol; Acquired Immune-Deficiency Syndrome (AIDS)
based upon current CDC definition (HIV testing is not required for entry into this protocol)
8. No active systemic lupus, erythematosus, or any history of scleroderma or dermatomyositis with active
rash
9. Medical, psychiatric, or other condition that would prevent the patient from receiving the protocol
therapy or providing informed consent
Prior concurrent therapy:
1. See disease characteristics
2. Study entry must be within 50 days of last breast/axillary surgery and/or last chemotherapy
3. No treatment plan that includes regional-node radiotherapy
4. No prior radiotherapy to the breast or prior radiation to the region of the ipsilateral breast that would
result in overlap of radiation therapy fields
5. No intention to administer concurrent chemotherapy for current breast cancer
Interventions Active Comparator: Arm I participants undergo standard whole-breast radiotherapy (WBI) comprising in-
tensity-modulated radiation therapy (IMRT) or three-dimensional conformal radiotherapy (3D-CRT) 5 days
a week for 3-5 weeks followed by a sequential radiotherapy boost to the lumpectomy area 5 days a week for
1-1½ weeks in the absence of disease progression or unacceptable toxicity
Experimental: Arm II participants undergo accelerated hypofractionatedWBI comprising IMRT or 3D-CRT
with a concurrent boost to the lumpectomy area 5 days a week for 3 weeks in the absence of disease progression
or unacceptable toxicity
Outcomes Primary outcome measures: local control (time frame: from randomisation to the date of first local failure or
last follow-up. Analysis occurs after 245 local failures have been reported.) (Designated as safety issue: no)
Secondary outcome measures: overall survival (time frame: from randomisation to date of death due to any
cause or last follow-up.) (Designated as safety issue: no)
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NCT01349322 (Continued)
Disease-free survival (time frame: from randomisation to date of local-regional disease recurrence, distant
metastases, second primary, death due to any cause or last follow-up.) (Designated as safety issue: no)
Distant disease-free survival (time frame: from randomisation to date of distant metastases, second primary,
death due to any cause or last follow-up.) (Designated as safety issue: no)
Changes in breast-related symptoms and side effects and cosmesis (time frame: from randomisation to 3 years.
) (Designated as safety issue: no)
Correlation between dose-volume data and both adverse events and efficacy (time frame: from randomisation
to end of follow-up.) (Designated as safety issue: no)
Treatment cost of accelerated course of hypofractionated WBI versus standard WBI with a sequential boost
(time frame: from randomisation to end of treatment.) (Designated as safety issue: no)
Starting date May 2011- Aug 2020
Contact information Principal investigator: Frank Vicini St Joseph Mercy Oakland
Notes N = 2312
NCT01413269
Trial name or title Phase 3 Open-labeled Randomized Clinical Study of Comparing Hypofractionated and Conventional Ra-
diotherapy for Breast Cancer Patients After Breast Conservative Surgery
Methods Phase III RCT
Participants Women aged 18-70 years
Inclusion Criteria:
1. KPS >= 60
2. histology confirmed invasive breast cancer
3. received breast conservative surgery (wide local excision and axilla dissection, or axillary sentinel node
biopsy if sentinel node is negative)
4. surgical margins negative
5. primary tumour ≤ 5 cm in the largest diameter
6. no internal mammary node or supraclavicular node metastases or distant metastasis
7. can tolerate chemotherapy, hormone therapy (if needed) and radiotherapy
8. for participants not needing chemotherapy enrolment date is required no more than 8 weeks from
surgery date
9. for participants with chemotherapy first enrolment date is required no more than 8 weeks from the last
date of chemotherapy
10. participants signed written inform consent form
Exclusion Criteria:
1. ductal carcinoma in situ
2. prior neoadjuvant chemotherapy
3. prior breast cancer history
4. bilateral breast cancer
5. pregnant or lactating
6. prior or concomitant malignant tumour excluded skin cancer (not malignant melanoma) and cervix
carcinoma in situ
7. active collagen vascular disease
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8. prior neoadjuvant hormone therapy
9. immediate ipsilateral breast reconstruction
Interventions Experimental: hypofractionation radiotherapy, irradiation to the whole breast to a total dose of 43.5 Gy,at
2.9 Gy per fraction, 5 fractions a week, followed by tumour bed boost of 8.7 Gy, at 2.9 Gy per fraction 5
fractions a week
Active Comparator: conventional fractionation radiotherapy, irradiation to the whole breast to a total dose
of 50 Gy,at 2.0 Gy per fraction, 5 fractions a week, followed by tumour bed boost of 10 Gy, at 2.0 Gy per
fraction 5 fractions a week
Outcomes Primary outcome measures: in-breast recurrence rate (time frame: 5 years) evidence of ipsilateral breast local
recurrence confirmed by histology
Secondary outcome measures: regional node recurrence rate (time frame: 5 years) ipsilateral axillary node,
internal mammary node and supraclavicular node recurrence confirmed by physical examination, image
evaluation or histology; disease-free survival (time frame: 5 years); overall survival (time Frame: 5 years); acute
toxicity (time frame: 6 months) radiation dermatitis and radiation pneumonitis evaluated and graded by
CTC3.0 criteria; late complication (time frame: 3-10 years) breast cosmetic effect, ischaemic heart disease,
rib fracture, arm edema and shoulder joint dysfunction
Starting date June 2010-June 2019
Contact information Study Chair: Ye-xiong Li, Principal Investigator: Shu-lian Wang Chinese Academy of Medical Science
Notes N = 630
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D A T A A N D A N A L Y S E S
Comparison 1. Hypofractionation versus conventional fractionation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Local recurrence-free survival
(LR-FS)
6 Hazard Ratio (95% CI) Subtotals only
1.1 LR-FS at median 3.5 years
follow-up
2 955 Hazard Ratio (95% CI) 0.18 [0.03, 1.13]
1.2 LR-FS at median 10 years
follow-up
4 7095 Hazard Ratio (95% CI) 0.94 [0.77, 1.15]
2 LR-FS by dose 4 5732 Hazard Ratio (95% CI) 0.89 [0.70, 1.14]
2.1 EQD2 less than 50 Gy 3 5685 Hazard Ratio (95% CI) 0.90 [0.71, 1.14]
2.2 EQD2 dose ≥ 50 Gy 1 47 Hazard Ratio (95% CI) 0.47 [0.04, 5.20]
3 Cosmesis (fair/poor) 4 2103 Risk Ratio (M-H, Fixed, 95% CI) 0.90 [0.81, 1.01]
4 Overall survival (OS) 3 5685 Hazard Ratio (95% CI) 0.91 [0.80, 1.03]
4.1 OS at 10 years median
follow-up
3 5685 Hazard Ratio (95% CI) 0.91 [0.80, 1.03]
5 Acute skin radiation toxicity 2 357 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.22, 0.45]
6 Late skin toxicity 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Late skin RT toxicity at
10 years
1 455 Risk Ratio (M-H, Fixed, 95% CI) 1.09 [0.60, 1.99]
7 Late subcutaneous toxicity
(fibrosis))
4 5130 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.83, 1.05]
7.1 Subcutaneous skin toxicity
at 5 years
1 806 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.85, 1.35]
7.2 Subcutaneous skin toxicity
at 10 years
3 4324 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.78, 1.02]
8 Telangiectasia 3 4632 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.52, 0.91]
9 Breast oedema 3 4140 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.51, 0.78]
10 Breast shrinkage 2 3869 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.79, 1.00]
11 Ischaemic heart disease
(left-sided tumours)
2 4451 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.28, 1.79]
12 Rib fractures 3 5685 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.25, 3.10]
13 Breast cancer-specific survival 3 5685 Hazard Ratio (95% CI) 0.91 [0.78, 1.06]
14 Relapse-free survival 3 5685 Hazard Ratio (95% CI) 0.93 [0.82, 1.05]
14.1 Relapse-free survival at
median 5 years follow-up
1 1234 Hazard Ratio (95% CI) 1.10 [0.81, 1.49]
14.2 Relapse-free survival at
10 years median follow-up
2 4451 Hazard Ratio (95% CI) 0.90 [0.78, 1.03]
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Analysis 1.1. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 1 Local
recurrence-free survival (LR-FS).
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 1 Local recurrence-free survival (LR-FS)
Study or subgroup Hypofractionation Conventional Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 LR-FS at median 3.5 years follow-up
FAST 2011 0/607 2/301 39.6 % 0.04 [ 0.00, 0.74 ]
Saha 2009 1/24 2/23 60.4 % 0.47 [ 0.04, 5.20 ]
Subtotal (95% CI) 631 324 100.0 % 0.18 [ 0.03, 1.13 ]
Heterogeneity: Chi2 = 1.66, df = 1 (P = 0.20); I2 =40%
Test for overall effect: Z = 1.83 (P = 0.067)
2 LR-FS at median 10 years follow-up
Owen 2006a 99/940 48/470 32.8 % 1.03 [ 0.73, 1.45 ]
START A 2008 84/1487 40/749 27.8 % 1.06 [ 0.73, 1.54 ]
START B 2008 36/1110 50/1105 20.8 % 0.71 [ 0.46, 1.09 ]
Whelan 2002b 39/622 41/612 18.7 % 0.92 [ 0.59, 1.46 ]
Subtotal (95% CI) 4159 2936 100.0 % 0.94 [ 0.77, 1.15 ]
Heterogeneity: Chi2 = 2.36, df = 3 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
Test for subgroup differences: Chi2 = 3.09, df = 1 (P = 0.08), I2 =68%
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.2. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 2 LR-FS by dose.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 2 LR-FS by dose
Study or subgroup Hypofractionation Conventional Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 EQD2 less than 50 Gy
START A 2008 84/1487 40/749 40.9 % 1.06 [ 0.73, 1.54 ]
START B 2008 36/1110 50/1105 30.6 % 0.71 [ 0.46, 1.09 ]
Whelan 2002b 39/622 41/612 27.5 % 0.92 [ 0.59, 1.46 ]
Subtotal (95% CI) 3219 2466 99.0 % 0.90 [ 0.71, 1.14 ]
Heterogeneity: Chi2 = 1.96, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
2 EQD2 dose≥ 50 Gy
Saha 2009 1/24 2/23 1.0 % 0.47 [ 0.04, 5.20 ]
Subtotal (95% CI) 24 23 1.0 % 0.47 [ 0.04, 5.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 100.0 % 0.89 [ 0.70, 1.14 ]
Heterogeneity: Chi2 = 2.23, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Chi2 = 0.27, df = 1 (P = 0.60), I2 =0.0%
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.3. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 3 Cosmesis
(fair/poor).
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 3 Cosmesis (fair/poor)
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Owen 2006a 291/535 165/271 64.6 % 0.89 [ 0.79, 1.01 ]
Saha 2009 6/24 3/23 0.9 % 1.92 [ 0.54, 6.77 ]
Taher 2004 6/15 11/15 3.2 % 0.55 [ 0.27, 1.09 ]
Whelan 2002b 100/616 105/604 31.3 % 0.93 [ 0.73, 1.20 ]
Total (95% CI) 1190 913 100.0 % 0.90 [ 0.81, 1.01 ]
Total events: 403 (Hypofractionation), 284 (Conventional)
Heterogeneity: Chi2 = 3.52, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 1.73 (P = 0.084)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.4. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 4 Overall
survival (OS).
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 4 Overall survival (OS)
Study or subgroup Hypofractionation Conventional Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 OS at 10 years median follow-up
START A 2008 262/1487 130/749 37.0 % 1.01 [ 0.82, 1.25 ]
START B 2008 159/1110 192/1105 36.8 % 0.80 [ 0.65, 0.99 ]
Whelan 2002b 122/622 126/612 26.2 % 0.94 [ 0.73, 1.21 ]
Total (95% CI) 100.0 % 0.91 [ 0.80, 1.03 ]
Heterogeneity: Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.5. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 5 Acute skin
radiation toxicity.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 5 Acute skin radiation toxicity
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
FAST 2011 27/217 51/110 88.3 % 0.27 [ 0.18, 0.40 ]
Taher 2004 6/15 9/15 11.7 % 0.67 [ 0.32, 1.40 ]
Total (95% CI) 232 125 100.0 % 0.32 [ 0.22, 0.45 ]
Total events: 33 (Hypofractionation), 60 (Conventional)
Heterogeneity: Chi2 = 4.49, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 6.39 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
Analysis 1.6. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 6 Late skin
toxicity.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 6 Late skin toxicity
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Late skin RT toxicity at 10 years
Whelan 2002b 21/235 18/220 100.0 % 1.09 [ 0.60, 1.99 ]
Subtotal (95% CI) 235 220 100.0 % 1.09 [ 0.60, 1.99 ]
Total events: 21 (Hypofractionation), 18 (Conventional)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours hypofractionation Favours conventional
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Analysis 1.7. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 7 Late
subcutaneous toxicity (fibrosis)).
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 7 Late subcutaneous toxicity (fibrosis))
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Subcutaneous skin toxicity at 5 years
Owen 2006a 163/535 77/271 21.8 % 1.07 [ 0.85, 1.35 ]
Subtotal (95% CI) 535 271 21.8 % 1.07 [ 0.85, 1.35 ]
Total events: 163 (Hypofractionation), 77 (Conventional)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 Subcutaneous skin toxicity at 10 years
START A 2008 260/1244 142/616 40.5 % 0.91 [ 0.76, 1.09 ]
START B 2008 129/1006 153/1003 32.7 % 0.84 [ 0.68, 1.04 ]
Whelan 2002b 28/235 23/220 5.1 % 1.14 [ 0.68, 1.92 ]
Subtotal (95% CI) 2485 1839 78.2 % 0.89 [ 0.78, 1.02 ]
Total events: 417 (Hypofractionation), 318 (Conventional)
Heterogeneity: Chi2 = 1.17, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
Total (95% CI) 3020 2110 100.0 % 0.93 [ 0.83, 1.05 ]
Total events: 580 (Hypofractionation), 395 (Conventional)
Heterogeneity: Chi2 = 2.98, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 1.81, df = 1 (P = 0.18), I2 =45%
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.8. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 8 Telangiectasia.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 8 Telangiectasia
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shaitelman 2015 0/129 1/142 1.3 % 0.37 [ 0.02, 8.92 ]
START A 2008 61/1456 42/730 51.0 % 0.73 [ 0.50, 1.07 ]
START B 2008 34/1094 52/1081 47.7 % 0.65 [ 0.42, 0.99 ]
Total (95% CI) 2679 1953 100.0 % 0.68 [ 0.52, 0.91 ]
Total events: 95 (Hypofractionation), 95 (Conventional)
Heterogeneity: Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 2.63 (P = 0.0086)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.9. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 9 Breast
oedema.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 9 Breast oedema
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Shaitelman 2015 2/129 7/142 3.4 % 0.31 [ 0.07, 1.49 ]
START A 2008 110/1244 78/616 52.9 % 0.70 [ 0.53, 0.92 ]
START B 2008 49/1006 86/1003 43.7 % 0.57 [ 0.40, 0.80 ]
Total (95% CI) 2379 1761 100.0 % 0.63 [ 0.51, 0.78 ]
Total events: 161 (Hypofractionation), 171 (Conventional)
Heterogeneity: Chi2 = 1.67, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 4.31 (P = 0.000016)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
66Fraction size in radiation therapy for breast conservation in early breast cancer (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 10 Breast
shrinkage.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 10 Breast shrinkage
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
START A 2008 308/1244 165/616 46.3 % 0.92 [ 0.79, 1.09 ]
START B 2008 221/1006 256/1003 53.7 % 0.86 [ 0.74, 1.01 ]
Total (95% CI) 2250 1619 100.0 % 0.89 [ 0.79, 1.00 ]
Total events: 529 (Hypofractionation), 421 (Conventional)
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.044)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
Analysis 1.11. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 11 Ischaemic
heart disease (left-sided tumours).
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 11 Ischaemic heart disease (left-sided tumours)
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
START A 2008 5/1487 4/749 51.5 % 0.63 [ 0.17, 2.34 ]
START B 2008 4/1110 5/1105 48.5 % 0.80 [ 0.21, 2.96 ]
Total (95% CI) 2597 1854 100.0 % 0.71 [ 0.28, 1.79 ]
Total events: 9 (Hypofractionation), 9 (Conventional)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.12. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 12 Rib
fractures.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 12 Rib fractures
Study or subgroup Hypofractionation Conventional Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
START A 2008 1/1487 0/749 12.9 % 1.51 [ 0.06, 37.07 ]
START B 2008 3/1105 3/1110 57.9 % 1.00 [ 0.20, 4.97 ]
Whelan 2002b 0/622 1/612 29.2 % 0.33 [ 0.01, 8.04 ]
Total (95% CI) 3214 2471 100.0 % 0.87 [ 0.25, 3.10 ]
Total events: 4 (Hypofractionation), 4 (Conventional)
Heterogeneity: Chi2 = 0.50, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.13. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 13 Breast
cancer-specific survival.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 13 Breast cancer-specific survival
Study or subgroup Hypofractionation Conventional Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
START A 2008 181/1487 92/749 38.0 % 0.98 [ 0.76, 1.26 ]
START B 2008 106/1110 130/1105 36.4 % 0.79 [ 0.61, 1.02 ]
Whelan 2002b 82/622 82/612 25.6 % 0.98 [ 0.72, 1.33 ]
Total (95% CI) 100.0 % 0.91 [ 0.78, 1.06 ]
Heterogeneity: Chi2 = 1.72, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
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Analysis 1.14. Comparison 1 Hypofractionation versus conventional fractionation, Outcome 14 Relapse-
free survival.
Review: Fraction size in radiation therapy for breast conservation in early breast cancer
Comparison: 1 Hypofractionation versus conventional fractionation
Outcome: 14 Relapse-free survival
Study or subgroup Hypofractionation Conventional Hazard Ratio Weight Hazard Ratio
n/N n/N
Exp[(O-
E)/V],Fixed,95%
CI
Exp[(O-
E)/V],Fixed,95%
CI
1 Relapse-free survival at median 5 years follow-up
Whelan 2002b 0/622 0/612 17.0 % 1.10 [ 0.81, 1.49 ]
Subtotal (95% CI) 622 612 17.0 % 1.10 [ 0.81, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 Relapse-free survival at 10 years median follow-up
START A 2008 312/1487 154/749 42.3 % 1.03 [ 0.85, 1.24 ]
START B 2008 182/1110 222/1105 40.7 % 0.78 [ 0.64, 0.95 ]
Subtotal (95% CI) 2597 1854 83.0 % 0.90 [ 0.78, 1.03 ]
Heterogeneity: Chi2 = 3.81, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 1.56 (P = 0.12)
Total (95% CI) 100.0 % 0.93 [ 0.82, 1.05 ]
Heterogeneity: Chi2 = 5.23, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Chi2 = 1.42, df = 1 (P = 0.23), I2 =29%
0.01 0.1 1 10 100
Favours hypofractionation Favours conventional
A D D I T I O N A L T A B L E S
Table 1. EORTC Cosmetic Rating System
Global cosmetic
0 No difference or excellent
1 Small difference or good
2 Moderate difference or fair
3 Large difference or poor
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Table 2. RTOG CTCAE acute skin toxicity
Grade Description
0 No visible change
1 Faint/dull erythema
2 Tender/bright erythema +/- dry desquamation
3 Patchy moist desquamation, moderate erythema
4 Confluent moist desquamation, pitting oedema
Table 3. NCI CTCAE Version 4.0
Grade Description
I Mild; asymptomatic or mild
symptoms; clinical or diagnostic
observations only; intervention not
indicated
2 Moderate; minimal, local or
noninvasive intervention indicated;
limiting age-appropriate
instrumental ADL
3 Severe or medically significant but
not immediately life-threatening;
hospitalisation or prolongation of
hospitalisation indicated; disabling;
limiting self-care ADL
3 Life-threatening consequences;
urgent intervention indicated
3 Death related to adverse event
ADL: activities of daily living
Table 4. Conversion of altered fractionation regimen to EQD2
Study Dose Fractions EQD2
Owen 2006a 42.9 Gy 13 52.19
Control arm dose 50.0 Gy 25 50.00
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Table 4. Conversion of altered fractionation regimen to EQD2 (Continued)
FAST 2011
Saha 2009
30.0 Gy 5 50.00
START A 2008 41.6 Gy 13 49.92
FAST 2011 28.5 Gy 5 46.07
Whelan 2002b
Shaitelman 2015
Taher 2004
42.5 Gy 16 45.76
Owen 2006a
START A 2008
39.0 Gy 13 45.50
START B 2008
Patni 2012
40.0 Gy 15 42.90
Table 5. RTOG/EORTC late radiation morbidity scale
Score Definition
0 No toxicity
1 Slight toxicity
2 Moderate toxicity
3 Marked toxicity
4 Severe toxicity
Table 6. Induration scale (Owen 2006a)
Score Definition
0 None
1 Mild
2 Moderate
3 Marked
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Table 7. START A & B Late RT toxicity scale
Grade Description
0 “none”
I “a little”
II “quite a bit”
III “very much”
Table 8. Boost for women treated with breast conservation
STUDY Breast conservation Boost experimental arm Boost control arm Total
START A 2008 1900 41.6 Gy/13 fractions arm:
391/750 (61%)
39 Gy/13 fractions arm:
380/737 (60.5%)
Total number with boost:
771/1269 (61%)
381/631 (60%) 1152/1900 (61%)
START B 2008 2038 446/1018 (44%) 422/1020
(41%)
868/2038
(43%)
Owen 2006a 1410 - - 1051/1410 (75%)
FAST 2011 729 0/613 0/302 0/729 (0%)
Whelan 2002b 1234 0/622 0/612 0/1234 (0%)
Saha 2009 47 - - 41/47 (0%)
Taher 2004 30 15/15 0/15 15/30 (50%)
Shaitelman 2015 287 138/138 149/149 287/287 (100%)
Patni 2012 40 20/20 20/20 40/40
Total number boosted 3454/7715 (44%)
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Table 9. Cosmesis scale (Owen 2006a)
Breast Cosmesis
Excellent
Good
Fair
Poor
Table 10. ASTRO ’suitable’ patients for hypofractionated whole breast radiotherapy
Patient is 50 years or older at diagnosis
Pathologic stage is T1-2 N0 and patient has been treated with breast conserving surgery
Patient has not been treated with systemic chemotherapy
Within the breast along the central axis, the minimum dose is no less than 93% and maximum dose is no greater than 107% of the
prescription dose (7%;) (as calculated with 2-dimensional treatment planning without heterogeneity corrections)
T: tumour
N: lymph node
A P P E N D I C E S
Appendix 1. CENTRAL
1 MeSH descriptor: [Breast Neoplasms] explode all trees
2 breast and (tumour* or tumor*)
3 breast and (cancer* or neoplas* or adenocarcinoma)
4 1 or 2 or 3
5 MESH DESCRIPTOR: [Radiotherapy Dosage] explode all trees
6 MESH DESCRIPTOR: [Dose-Response Relationship, Radiation] explode all trees
7 MESH DESCRIPTOR: [Dose fractionation] explode all trees
8 5 or 6 or 7
9 radiotherap* or (radiation therap*)
10 dose or dosage or fraction$
11 4 and 9 and 10
12 8 or 11
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Appendix 2. MEDLINE (Ovid)
1 breast neoplasms/
2 (breast cancer or breast adenocarcinoma).ti.
3 1 or 2
4 rt.fs.
5 radiotherapy dosage/
6 dose response relationship, radiation/
7 Dose Fractionation/
8 radiotherapy/
9 radiotherapy adjuvant/
10 exp radiotherapy, computer assisted/
11 or/4-10
12 (letter or news).pt.
13 (systematic$ adj3 (review$ or overview)).mp.
14 meta-analysis/ or meta-analysis.pt.
15 13 or 14
16 3 and 11 and 15
17 16 not 12
18 randomized controlled trials/ or randomized controlled trial.pt.
19 randomization/ or double blind method/ or single blind method/
20 18 or 19
21 3 and 11 and 20
22 21 not 12
23 22 not 17
24 (breast cancer or breast neoplasm$ or breast adenocarcinoma).ti,ab.
25 (radiotherapy or radiation therapy).ti,ab.
26 (dose or dosage or fraction$).mp.
27 24 and 25 and 26
28 20 and 27
29 28 not 23
30 23 or 29
31 17 or 30
Appendix 3. EMBASE (Ovid)
1 breast cancer/ or breast adenocarcinoma/ or breast carcinoma/
2 (breast cancer or breast adenocarcinoma).ti.
3 1 or 2
4 Randomized Controlled Trial/
5 RANDOMIZATION/
6 Double Blind Procedure/
7 Single Blind Procedure/
8 or/4-7
9 3 and 8
10 radiotherapy/
11 radiation response/
12 radiation dose fractionation/
13 radiation dose/
14 radiation depth dose/
15 computer assisted radiotherapy/
16 rt.fs.
17 or/10-16
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18 17 and 9
19 (breast cancer or breast neoplasm$ or breast adenocarcinoma).tw.
20 (radiotherapy or radiation).tw.
21 (dose or doses or dosage or fraction$).tw.
22 and/19-21
23 9 and 22
24 18 or 23
25 letter/
26 24 not 25
27 meta-analysis/
28 (meta-analy$ or metaanaly$).mp.
29 (systematic$ adj3 (review$ or overview)).mp.
30 or/27-29
31 22 and 30
32 3 and 17 and 30
33 31 or 32
Appendix 4. WHO ICTRP Search Portal
Advanced search (with Recruitment set at ALL):
Search 1.
Condition field: breast cancer
Intervention field: fraction size AND radiation
Search 2.
Condition field: adenocarcinoma AND breast
Intervention field: radiation
Search 3.
Condition field: adenocarcinoma AND breast
Intervention field: irradiation
Search 4.
Condition: breast cancer
Intervention field: irradiation
Search 5.
Condition: breast cancer
Intervention: hypofractionated radiation
Appendix 5. ClinicalTrials.gov
Basic Searches:
1. breast cancer AND radiotherapy AND fraction
2. breast cancer AND radiotherapy AND breast conservation
Advanced Searches:
1.Title: fraction size in radiation treatment for breast conservation in early breast cancer
Recruitment:All studies
Study Results: All studies
Study Type: All studies
Gender: All studies
2.Conditions: breast cancer
Intervention: (radiotherapy OR radiation therapy) AND (dose OR fraction)
Recruitment:All studies
Study Results: All studies
Study Type: All studies
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Gender: All studies
Appendix 6. opengrey.org
1. (breast cancer OR breast neoplasm* OR breast adenocarcinoma) AND (radiation OR irradiation OR radiotherapy OR radio-
therapy))
WH A T ’ S N E W
Last assessed as up-to-date: 23 May 2015.
Date Event Description
23 May 2015 New citation required but conclusions have not changed Five new studies added, adding 1133 participants
23 May 2015 New search has been performed Performed search for new studies on 23 May 2015
H I S T O R Y
Protocol first published: Issue 4, 2002
Review first published: Issue 3, 2008
Date Event Description
18 September 2009 New citation required and conclusions have changed Two new studies included, adding 4451 participants.
Conclusions changed and new outcomes presented
23 June 2009 New search has been performed Performed search for new studies on the 23rd June
2009.
11 April 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
The protocol was co-authored by Melissa James, Margot Lehman, Brigid Hickey, Phil Hider and Mark Jeffery.
Brigid Hickey was involved in conceiving and designing the review, screening papers against the inclusion criteria, appraising the quality
of papers, extracting data, analysing data, providing a clinical perspective, writing the review, providing general advice and securing
funding for the initial review and the update. Brigid Hickey was involved in screening papers against inclusion criteria, appraising the
quality of papers, extracting data, analysing data, providing a clinical perspective, writing the review, constructing the Summary of
Findings Table responding to peer reviewers’ comments and providing general advice for the 2016 update.
Melissa James was involved in conceiving and designing the review, writing the protocol, screening search results, organising paper
retrieval, screening papers against inclusion criteria, appraising quality of papers, writing to authors, screening data on unpublished
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studies, providing a clinical perspective and writing the review. Melissa James provided clinical perspective, editing and checked the
data for the 2016 update.
Margot Lehman was involved in screening papers against the inclusion criteria, appraising the quality of papers, securing funding,
extracting data, providing a clinical perspective and providing advice regarding the review, and securing funding for the initial review
and the update. Margot Lehman was involved in screening papers against inclusion criteria, appraising quality of papers, securing
funding, extracting data, providing a clinical perspective and providing advice regarding the review for the 2016 update.
Phil Hider was involved in designing the review, doing the search, providing methodological perspective, writing the review, and
providing general advice regarding the review.
Mark Jeffery was involved in designing the review, co-ordinating the review, screening search results, organising paper retrieval, screening
papers against the inclusion criteria, appraising quality of papers, writing to authors, obtaining data on unpublished studies, providing
clinical perspective and writing the review. Mark Jeffery provided clinical perspective and editing for the update.
Daniel Francis was involved in co-ordinating the review, doing the search, screening search results, organising paper retrieval, screening
against the inclusion criteria, writing to authors, providing a methodological perspective, and providing general advice for all versions
of this review.
Adrienne See performed the literature searches for this and previous versions of the review.
D E C L A R A T I O N S O F I N T E R E S T
BH: None known.
MJ: None known.
ML: None known.
PH: None known.
MJ: None known.
DF: None known.
S O U R C E S O F S U P P O R T
Internal sources
• Princess Alexandra Hospital Cancer Collaborative Group, Australia.
External sources
• No sources of support supplied
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Women with T3 tumours (that is tumour size greater than 5 cm) were eligible for the START A 2008 and START B 2008 studies.
They comprised 1.6% (22/1410) of the women studied in Owen 2006a. T stage was not reported in START A 2008 and START B
2008, but 0.15% (702/4451) women had tumours larger than 3 cm. T3 tumours (larger than 5 cm) accounted for 0.02% (22/7513)
of the total number of women studied.
With this update, we have adapted the review to meet the MECIR guidelines for conduct and reporting of systematic reviews.
We now report local recurrence-free survival as our primary outcome measure (in distinct to local recurrence). We have reported time-
to event data where possible for cancer-related outcomes. We also report breast cancer-specific survival rather than cancer-specific
mortality (as time-to-event endpoints are preferred for cancer outcomes) in order to be consistent.
Radiation doses converted to EQD2, whereas we used BED initially, this is because it is more meaningful for clinicians.
We performed subgroup analysis based on study arm dose (less than 50Gy versus 50Gy or more) and length of follow-up (4.2 years
versus approximately 10 years).
We have rationalised the Table of Excluded Studies, so it only includes those studies one might reasonably think might be eligible for
inclusion. Those excluded because they are not randomised have been removed from this table.
We included Shaitelman 2015, even though they included DCIS. The outcomes reported relate to acute toxicity, cosmetic outcome
and quality of life, so we felt it was appropriate to include the study.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dose Hypofractionation; Breast Neoplasms [∗radiotherapy; surgery]; Combined Modality Therapy [methods]; Dose Fractionation;
Mastectomy, Segmental; Radiation Injuries [complications; mortality]; Randomized Controlled Trials as Topic
MeSH check words
Female; Humans
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